GC06 Nuevas terapias en cáncer

Autores/as: Guil-Luna S, Rivas-Crespo A, Navarrete-Sirvent C, Mantrana A, Pera A, Mena-Osuna R, Toledano-Fonseca M, García-Ortíza MV, Villar C, Sanchez-Montero MT, Krueger J, Medina-Fernandez FJ, Haba-Rodríguez JDL, Auxiliadora E, Aranda E, Rudd CE, Rodríguez-Ariza A

Título: Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy

Revista: BIOMEDICINE & PHARMACOTHERAPY

DOI: 10.1016/j.biopha.2023.115592

IF: 7,5

Guil-Luna S, Rivas-Crespo A, Navarrete-Sirvent C, Mantrana A, Pera A, Mena-Osuna R, Toledano-Fonseca M, García-Ortíza MV, Villar C, Sanchez-Montero MT, Krueger J, Medina-Fernandez FJ, Haba-Rodríguez JDL, Auxiliadora E, Aranda E, Rudd CE, Rodríguez-Ariza A. Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy. BIOMEDICINE & PHARMACOTHERAPY. 2023. DOI: 10.1016/j.biopha.2023.115592. IF: 7,5 Q1 D1

Autores/as: Arjona-Sánchez A, Espinosa-Redondo E, Gutiérrez-Calvo A, Segura-Sampedro JJ, Pérez-Viejo E, Concepción-Martín V, Sánchez-García S, García-Fadrique A, Prieto-Nieto I, Barrios-Sanchez P, Torres-Melero J, Faraco MR, Prada-Villaverde A, Carrasco-Campos J, Artiles-Armas M, Villarejo-Campos P, Ortega-Pérez G, Boldo-Roda E, Sánchez-Hidalgo JM, Casado-Adam A, Rodríguez-Ortiz L, Aranda E, Cano-Osuna MT, Díaz-López C, Romero-Ruiz A, Briceño-Delgado J, Rufián-Peña S

Título: Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer A Phase 3 Randomized Clinical Trial

Revista: JAMA SURGERY

DOI: 10.1001/jamasurg.2023.0662

IF: 16,9

Arjona-Sánchez A, Espinosa-Redondo E, Gutiérrez-Calvo A, Segura-Sampedro JJ, Pérez-Viejo E, Concepción-Martín V, Sánchez-García S, García-Fadrique A, Prieto-Nieto I, Barrios-Sanchez P, Torres-Melero J, Faraco MR, Prada-Villaverde A, Carrasco-Campos J, Artiles-Armas M, Villarejo-Campos P, Ortega-Pérez G, Boldo-Roda E, Sánchez-Hidalgo JM, Casado-Adam A, Rodríguez-Ortiz L, Aranda E, Cano-Osuna MT, Díaz-López C, Romero-Ruiz A, Briceño-Delgado J, Rufián-Peña S. Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer A Phase 3 Randomized Clinical Trial. JAMA SURGERY. 2023. 683-691. DOI: 10.1001/jamasurg.2023.0662. IF: 16,9 Q1 D1

Autores/as: Garcia-Torres F, Garcia-Carmona M, Rubio S, Luque B, Gomez-Solis A, Aranda E

Título: Feasibility study of a mobile application (ACT-ON) to complement acceptance and commitment therapy (ACT) intervention in cancer patients

Revista: INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS

DOI: 10.1016/j.ijmedinf.2023.105131

IF: 4,9

Garcia-Torres F, Garcia-Carmona M, Rubio S, Luque B, Gomez-Solis A, Aranda E. Feasibility study of a mobile application (ACT-ON) to complement acceptance and commitment therapy (ACT) intervention in cancer patients. INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS. 2023. DOI: 10.1016/j.ijmedinf.2023.105131. IF: 4,9 Q2 D4

Autores/as: Salguero J, Chamorro L, Gómez-Gómez E, de Benito P, Robles JE, Campos JP

Título: Kidney Survival Impact of Delayed Graft Function Depends on Kidney Donor Risk Index: A Single-Center Cohort Study

Revista: JOURNAL OF CLINICAL MEDICINE

DOI: 10.3390/jcm12196397

IF: 3,9

Salguero J, Chamorro L, Gómez-Gómez E, de Benito P, Robles JE, Campos JP. Kidney Survival Impact of Delayed Graft Function Depends on Kidney Donor Risk Index: A Single-Center Cohort Study. JOURNAL OF CLINICAL MEDICINE. 2023. DOI: 10.3390/jcm12196397. IF: 3,9 Q2 D4

Autores/as: Mena-Osuna R, Mantrana A, Guil-Luna S, Sanchez-Montero MT, Navarrete-Sirvent C, Morales-Ruiz T, Rivas-Crespo A, Toledano-Fonseca M, Garcia-Ortiz MV, Garcia-Jurado G, Gomez-Espana MA, Gonzalez-Fernandez R, Villar C, Medina-Fernandez FJ, Villalba JM, Aranda E, Rodriguez-Ariza A

Título: Metabolic shift underlies tumor progression and immune evasion in S-nitrosoglutathione reductase-deficient cancer

Revista: JOURNAL OF PATHOLOGY

DOI: 10.1002/path.6080

IF: 7,3

Mena-Osuna R, Mantrana A, Guil-Luna S, Sanchez-Montero MT, Navarrete-Sirvent C, Morales-Ruiz T, Rivas-Crespo A, Toledano-Fonseca M, Garcia-Ortiz MV, Garcia-Jurado G, Gomez-Espana MA, Gonzalez-Fernandez R, Villar C, Medina-Fernandez FJ, Villalba JM, Aranda E, Rodriguez-Ariza A. Metabolic shift underlies tumor progression and immune evasion in S-nitrosoglutathione reductase-deficient cancer. JOURNAL OF PATHOLOGY. 2023. 261-275. DOI: 10.1002/path.6080. IF: 7,3 Q1 D1

Autores/as: Salguero J, Chamorro L, Gomez-Gomez E, Robles JE, Campos JP

Título: Midterm Outcomes of Kidney Transplantation from Expanded Criteria Donors After Circulatory Death: A Single-Center Retrospective Cohort Study

Revista: EXPERIMENTAL AND CLINICAL TRANSPLANTATION

DOI: 10.6002/ect.2023.0076

IF: 0,9

Salguero J, Chamorro L, Gomez-Gomez E, Robles JE, Campos JP. Midterm Outcomes of Kidney Transplantation from Expanded Criteria Donors After Circulatory Death: A Single-Center Retrospective Cohort Study. EXPERIMENTAL AND CLINICAL TRANSPLANTATION. 2023. 481-486. DOI: 10.6002/ect.2023.0076. IF: 0,9 Q4 D

Autores/as: Grávalos C, Pereira F, Vera R, Arjona-Sánchez A, Losa F, Ramos I, García-Alfonso P, Gonzalez-Bayón L, Cascales-Campos PA, Aranda E

Título: Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-023-03204-7

IF: 3,4

Grávalos C, Pereira F, Vera R, Arjona-Sánchez A, Losa F, Ramos I, García-Alfonso P, Gonzalez-Bayón L, Cascales-Campos PA, Aranda E. Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement. CLINICAL & TRANSLATIONAL ONCOLOGY. 2023. 3378-3394. DOI: 10.1007/s12094-023-03204-7. IF: 3,4 Q3 D

Autores/as: Pedraza-Arevalo S, Alors-Perez E, Blazquez-Encinas R, Herrera-Martinez AD, Jimenz-Vacas JM, Fuentes-Fayos AC, Reyes O, Ventura S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Galvez-Moreno MA, Gahete MD, Ibanez-Costa A, Luque RM, Castano JP

Título: Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors

Revista: TRANSLATIONAL RESEARCH

DOI: 10.1016/j.trsl.2022.07.005

IF: 7,8

Pedraza-Arevalo S, Alors-Perez E, Blazquez-Encinas R, Herrera-Martinez AD, Jimenz-Vacas JM, Fuentes-Fayos AC, Reyes O, Ventura S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Galvez-Moreno MA, Gahete MD, Ibanez-Costa A, Luque RM, Castano JP. Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors. TRANSLATIONAL RESEARCH. 2023. 63-73. DOI: 10.1016/j.trsl.2022.07.005. IF: 7,8 Q1 D2

Autores/as: Herrera-Martinez AD, Idougourram SL, Jimenez CM, Rodriguez-Alonso R, Echague RA, Palomino SC, Sanz AS, Garcia GM, Moreno MAG, Continente AC, Puertas MJM

Título: Standard Hypercaloric, Hyperproteic vs

Revista: Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial

DOI: 10.3390/nu15122726

IF: 5,9

Herrera-Martinez AD, Idougourram SL, Jimenez CM, Rodriguez-Alonso R, Echague RA, Palomino SC, Sanz AS, Garcia GM, Moreno MAG, Continente AC, Puertas MJM. Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial. NUTRIENTS. 2023. DOI: 10.3390/nu15122726. IF: 5,9 Q1 D2

Autores/as: Castillo LC, Morales LG, Lopez DR, Segura JS, Rosa JV, Curado FJA, Quesada JM, Pedregosa AB, Valiente JC, Gomez EG

Título: The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice

Revista: PROSTATE

DOI: 10.1002/pros.24515

IF: 2,8

Castillo LC, Morales LG, Lopez DR, Segura JS, Rosa JV, Curado FJA, Quesada JM, Pedregosa AB, Valiente JC, Gomez EG. The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice. PROSTATE. 2023. 765-772. DOI: 10.1002/pros.24515. IF: 2,8 Q2 D5

Autores/as: Fernandez-Perez MP, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, Font A, Vazquez-Estevez S, Gonzalez-del-Alba A, Wetterskog D, Antonarakis ES, Mellado B, Fernandez-Calvo O, Mendez-Vidal MJ, Climent MA, Duran I, Gallardo E, Sanchez AR, Santander C, Saez MI, Puente J, Tudela J, Martinez A, Lopez-Andreo MJ, Padilla J, Lozano R, Hervas D, Luo J, de Giorgi U, Castellano D, Attard G, Grande E, Gonzalez-Billalabeitia E

Título: A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide

Revista: PROSTATE

DOI: 10.1002/pros.24469

IF: 2,8

Fernandez-Perez MP, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, Font A, Vazquez-Estevez S, Gonzalez-del-Alba A, Wetterskog D, Antonarakis ES, Mellado B, Fernandez-Calvo O, Mendez-Vidal MJ, Climent MA, Duran I, Gallardo E, Sanchez AR, Santander C, Saez MI, Puente J, Tudela J, Martinez A, Lopez-Andreo MJ, Padilla J, Lozano R, Hervas D, Luo J, de Giorgi U, Castellano D, Attard G, Grande E, Gonzalez-Billalabeitia E. A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide. PROSTATE. 2023. 376-384. DOI: 10.1002/pros.24469. IF: 2,8 Q2 D5

Autores/as: Filella X, González A, Augé JM, Barco A, Carbonell R, Gaspar MJ, Martínez-Peinado A, Barrios CP, Sánchez-Carbayo M, Santotoribio JD, Trapé J

Título: A new approach to prostate cancer screening

Revista: ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO

DOI: 10.1515/almed-2023-0082

IF: 1

Filella X, González A, Augé JM, Barco A, Carbonell R, Gaspar MJ, Martínez-Peinado A, Barrios CP, Sánchez-Carbayo M, Santotoribio JD, Trapé J. A new approach to prostate cancer screening. ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO. 2023. 207-211. DOI: 10.1515/almed-2023-0082. IF: 1 Q4 D

Autores/as: Toledano-Fonseca M, Gomez-Espana MA, Elez E, Gravalos C, Garcia-Alfonso P, Rodriguez R, Losa F, Diaz IA, Grana B, Valladares-Ayerbes M, Garcia-Ortiz MV, Polo E, Salgado M, Rivera F, Safont MJ, Salud A, Ruiz-Casado A, Tabernero JM, Riesco MC, Rodriguez-Ariza A, Aranda E

Título: A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

Revista: BIOMEDICINE & PHARMACOTHERAPY

DOI: 10.1016/j.biopha.2023.114272

IF: 7,5

Toledano-Fonseca M, Gomez-Espana MA, Elez E, Gravalos C, Garcia-Alfonso P, Rodriguez R, Losa F, Diaz IA, Grana B, Valladares-Ayerbes M, Garcia-Ortiz MV, Polo E, Salgado M, Rivera F, Safont MJ, Salud A, Ruiz-Casado A, Tabernero JM, Riesco MC, Rodriguez-Ariza A, Aranda E. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients. BIOMEDICINE & PHARMACOTHERAPY. 2023. DOI: 10.1016/j.biopha.2023.114272. IF: 7,5 Q1 D1

Autores/as: Guil-Luna S, Sanchez-Cespedes R, Crespo AR, Fernandez MD, Sarmiento JAF, Rodriguez-Ariza A, Millan Y

Título: Analysis of cell-free DNA concentration, fragmentation patterns and TP53 gene expression in mammary tumor-bearing dogs: A pilot study

Revista: FRONTIERS IN VETERINARY SCIENCE

DOI: 10.3389/fvets.2023.1157878

IF: 3,2

Guil-Luna S, Sanchez-Cespedes R, Crespo AR, Fernandez MD, Sarmiento JAF, Rodriguez-Ariza A, Millan Y. Analysis of cell-free DNA concentration, fragmentation patterns and TP53 gene expression in mammary tumor-bearing dogs: A pilot study. FRONTIERS IN VETERINARY SCIENCE. 2023. DOI: 10.3389/fvets.2023.1157878. IF: 3,2 Q1 D1

Autores/as: Jimenez-Fonseca P, Sastre J, Garcia-Alfonso P, Gomez-Espana MA, Salud A, Gil S, Rivera F, Reina JJ, Quintero G, Valladares-Ayerbes M, Safont MJ, La Casta A, Robles-Diaz L, Garcia-Paredes B, Lopez RL, Guillot M, Gallego J, Alonso-Orduna V, Diaz-Rubio E, Aranda E

Título: Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNu-1 and Phase II VISNu-2 Randomized Trials

Revista: CLINICAL COLORECTAL CANCER

DOI: 10.1016/j.clcc.2023.02.004

IF: 3,4

Jimenez-Fonseca P, Sastre J, Garcia-Alfonso P, Gomez-Espana MA, Salud A, Gil S, Rivera F, Reina JJ, Quintero G, Valladares-Ayerbes M, Safont MJ, La Casta A, Robles-Diaz L, Garcia-Paredes B, Lopez RL, Guillot M, Gallego J, Alonso-Orduna V, Diaz-Rubio E, Aranda E. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNu-1 and Phase II VISNu-2 Randomized Trials. CLINICAL COLORECTAL CANCER. 2023. 222-230. DOI: 10.1016/j.clcc.2023.02.004. IF: 3,4 Q3 D

Autores/as: Calleja MA, Albanell J, Aranda E, Garcia-Foncillas J, Feliu A, Rivera F, Oyaguez I, Salinas-Ortega L, Alvarez JS

Título: Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

Revista: EUROPEAN JOURNAL OF HOSPITAL PHARMACY

DOI: 10.1136/ejhpharm-2021-002955

IF: 1,7

Calleja MA, Albanell J, Aranda E, Garcia-Foncillas J, Feliu A, Rivera F, Oyaguez I, Salinas-Ortega L, Alvarez JS. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2023. E40-E47. DOI: 10.1136/ejhpharm-2021-002955. IF: 1,7 Q4 D

Autores/as: García-Ortiz MV, Cano-Ramírez P, Toledano-Fonseca M, Cano MT, Inga-Saavedra E, Rodríguez-Alonso RM, Guil-Luna S, Gómez-España MA, Rodríguez-Ariza A, Aranda E

Título: Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer

Revista: CLINICAL EPIGENETICS

DOI: 10.1186/s13148-023-01535-4

IF: 5,7

García-Ortiz MV, Cano-Ramírez P, Toledano-Fonseca M, Cano MT, Inga-Saavedra E, Rodríguez-Alonso RM, Guil-Luna S, Gómez-España MA, Rodríguez-Ariza A, Aranda E. Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. CLINICAL EPIGENETICS. 2023. DOI: 10.1186/s13148-023-01535-4. IF: 5,7 Q2 D3

Autores/as: Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohe C, Farago AF, Lopez-Vilarino JA, Cullell-Young M, Nieto A, Vasco N, Gomez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sanchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Domine M, Paz-Ares L

Título: Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Revista: LANCET RESPIRATORY MEDICINE

DOI: 10.1016/S2213-2600(22)00309-5

IF: 76,2

Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohe C, Farago AF, Lopez-Vilarino JA, Cullell-Young M, Nieto A, Vasco N, Gomez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sanchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Domine M, Paz-Ares L. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. LANCET RESPIRATORY MEDICINE. 2023. 74-86. DOI: 10.1016/S2213-2600(22)00309-5. IF: 76,2 Q1 D1

Autores/as: García-Ortiz MV, Cano-Ramírez P, Toledano-Fonseca M, Aranda E, Rodríguez-Ariza A

Título: Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects

Revista: BIOMARKER RESEARCH

DOI: 10.1186/s40364-023-00528-y

IF: 11,1

García-Ortiz MV, Cano-Ramírez P, Toledano-Fonseca M, Aranda E, Rodríguez-Ariza A. Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. BIOMARKER RESEARCH. 2023. DOI: 10.1186/s40364-023-00528-y. IF: 11,1 Q1 D1

Autores/as: Bonilla CE, Montenegro P, O'Connor JM, Hernando-Requejo O, Aranda E, Llerena JP, Llontop A, Escobar JG, Romero MDD, Hernandez YB, Suarez BG, Batagelj EJ, Mushtaq AW, Garcia-Foncillas J

Título: Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer

Revista: CANCERS

DOI: 10.3390/cancers15174373

IF: 5,2

Bonilla CE, Montenegro P, O'Connor JM, Hernando-Requejo O, Aranda E, Llerena JP, Llontop A, Escobar JG, Romero MDD, Hernandez YB, Suarez BG, Batagelj EJ, Mushtaq AW, Garcia-Foncillas J. Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer. CANCERS. 2023. DOI: 10.3390/cancers15174373. IF: 5,2 Q2 D3

Autores/as: Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Mendez-Vidal MJ, Tjulandin S, Park SH, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grunwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Gordoa TA, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta C

Título: Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Revista: LANCET ONCOLOGY

DOI: 10.1016/S1470-2045(23)00049-9

IF: 51,1

Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Mendez-Vidal MJ, Tjulandin S, Park SH, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grunwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Gordoa TA, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta C. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. LANCET ONCOLOGY. 2023. 228-238. DOI: 10.1016/S1470-2045(23)00049-9. IF: 51,1 Q1 D1

Autores/as: Vidal J, Fernandez-Rodriguez MC, Casadevall D, Garcia-Alfonso P, Paez D, Guix M, Alonso V, Cano MT, Santos C, Duran G, Elez E, Manzano JL, Garcia-Carbonero R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C

Título: Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

Revista: CLINICAL CANCER RESEARCH

DOI: 10.1158/1078-0432.CCR-22-1696

IF: 11,5

Vidal J, Fernandez-Rodriguez MC, Casadevall D, Garcia-Alfonso P, Paez D, Guix M, Alonso V, Cano MT, Santos C, Duran G, Elez E, Manzano JL, Garcia-Carbonero R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. CLINICAL CANCER RESEARCH. 2023. 379-388. DOI: 10.1158/1078-0432.CCR-22-1696. IF: 11,5 Q1 D1

Autores/as: de Velasco G, Alonso-Gordoa T, Rodriguez-Vida A, Anguera G, Campayo M, Pinto A, Ortega EM, Gallardo E, Nunez NF, Garcia-Carbonero I, Reig O, Mendez-Vidal MJ, Fernandez-Calvo O, Cassinello NV, Torregrosa D, Lopez-Martin A, Rosero A, Valiente PG, de Espana CG, Climent MA, Santasusana MD, Sanchez AR, Gonzalez IC, Afonso R, del Muro XG, Casinello J, Fernandez-Parra EM, Sanchez LG, Afonso J, Polo SH, Asensio U

Título: Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib

Revista: CLINICAL GENITOURINARY CANCER

DOI: 10.1016/j.clgc.2022.11.021

IF: 3,2

de Velasco G, Alonso-Gordoa T, Rodriguez-Vida A, Anguera G, Campayo M, Pinto A, Ortega EM, Gallardo E, Nunez NF, Garcia-Carbonero I, Reig O, Mendez-Vidal MJ, Fernandez-Calvo O, Cassinello NV, Torregrosa D, Lopez-Martin A, Rosero A, Valiente PG, de Espana CG, Climent MA, Santasusana MD, Sanchez AR, Gonzalez IC, Afonso R, del Muro XG, Casinello J, Fernandez-Parra EM, Sanchez LG, Afonso J, Polo SH, Asensio U. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. CLINICAL GENITOURINARY CANCER. 2023. e166-e174. DOI: 10.1016/j.clgc.2022.11.021. IF: 3,2 Q2 D4

Autores/as: Raimondi A, Nichetti F, Stahler A, Wasan HS, Aranda E, Randon G, Kurreck A, Meade AM, Diaz-Rubio E, Niger M, Stintzing S, Palermo F, Trarbach T, Prisciandaro M, Sommerhauser G, Fisher D, Morano F, Pietrantonio F, Modest DP

Título: Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials

Revista: EUROPEAN JOURNAL OF CANCER

DOI: 10.1016/j.ejca.2023.112945

IF: 8,4

Raimondi A, Nichetti F, Stahler A, Wasan HS, Aranda E, Randon G, Kurreck A, Meade AM, Diaz-Rubio E, Niger M, Stintzing S, Palermo F, Trarbach T, Prisciandaro M, Sommerhauser G, Fisher D, Morano F, Pietrantonio F, Modest DP. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. EUROPEAN JOURNAL OF CANCER. 2023. DOI: 10.1016/j.ejca.2023.112945. IF: 8,4 Q1 D2

Autores/as: Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, Vivanco GL, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benitez R, de la Rosa CA, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A

Título: Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

Revista: NEW ENGLAND JOURNAL OF MEDICINE

DOI: 10.1056/NEJMoa2215530

IF: 158,5

Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, Vivanco GL, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benitez R, de la Rosa CA, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023. 504-513. DOI: 10.1056/NEJMoa2215530. IF: 158,5 Q1 D1

Autores/as: Arpino G, Rodriguez JD, Ferrero JM, De Placido S, Klingbiel D, Revelant V, Wohlfarth C, Poppe R, Rimawi MF, PERTAIN Study Grp

Título: Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

Revista: CLINICAL CANCER RESEARCH

DOI: 10.1158/1078-0432.CCR-22-1092

IF: 11,5

Arpino G, Rodriguez JD, Ferrero JM, De Placido S, Klingbiel D, Revelant V, Wohlfarth C, Poppe R, Rimawi MF, PERTAIN Study Grp. Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. CLINICAL CANCER RESEARCH. 2023. 1468-1476. DOI: 10.1158/1078-0432.CCR-22-1092. IF: 11,5 Q1 D1

Autores/as: Grunwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Mendez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He CX, Okpara CE, McKenzie J, Choueiri TK

Título: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Revista: FRONTIERS IN ONCOLOGY

DOI: 10.3389/fonc.2023.1223282

IF: 4,7

Grunwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Mendez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He CX, Okpara CE, McKenzie J, Choueiri TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. FRONTIERS IN ONCOLOGY. 2023. DOI: 10.3389/fonc.2023.1223282. IF: 4,7 Q2 D4

Autores/as: Suarez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C, Srinivasan G, Mendez-Vidal MJ, Hartmaier R, Markovets A, Prendergast A, Szabados B, Mousa K, Powles T

Título: Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

Revista: JOURNAL OF CLINICAL ONCOLOGY

DOI: 10.1200/JCO.22.01414

IF: 45,3

Suarez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C, Srinivasan G, Mendez-Vidal MJ, Hartmaier R, Markovets A, Prendergast A, Szabados B, Mousa K, Powles T. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). JOURNAL OF CLINICAL ONCOLOGY. 2023. 2493-2502. DOI: 10.1200/JCO.22.01414. IF: 45,3 Q1 D1

Autores/as: Fita MJJ, Herranz UA, Mendez-Vidal MJ, Girones-Sarrio R, Munoz-Langa J, Sepulveda-Sanchez J, Mellado B, Alvarez-Fernandez C, Lopez LH, Lopez-Guerrero JA, Garcia-Casado Z, Calatrava A, Climent MA

Título: Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study

Revista: CANCERS

DOI: 10.3390/cancers15215223

IF: 5,2

Fita MJJ, Herranz UA, Mendez-Vidal MJ, Girones-Sarrio R, Munoz-Langa J, Sepulveda-Sanchez J, Mellado B, Alvarez-Fernandez C, Lopez LH, Lopez-Guerrero JA, Garcia-Casado Z, Calatrava A, Climent MA. Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study. CANCERS. 2023. DOI: 10.3390/cancers15215223. IF: 5,2 Q2 D3

Autores/as: Tibau A, Martinez MT, Ramos M, de la Cruz-merino L, Santaballa A, O'Connor M, Martinez-Janez N, Moreno F, Fernandez I, Virizuela JA, Alarcon J, de la Haba-rodriguez J, Sanchez-Rovira P, Albacar CR, Muino CB, Kelly C, Casas M, Bezares S, Rosell L, Albanell J

Título: Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Revista: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

DOI: 10.1177/17588359221148921

IF: 4,9

Tibau A, Martinez MT, Ramos M, de la Cruz-merino L, Santaballa A, O'Connor M, Martinez-Janez N, Moreno F, Fernandez I, Virizuela JA, Alarcon J, de la Haba-rodriguez J, Sanchez-Rovira P, Albacar CR, Muino CB, Kelly C, Casas M, Bezares S, Rosell L, Albanell J. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2023. DOI: 10.1177/17588359221148921. IF: 4,9 Q2 D4

Autores/as: Pericay C, Montes AF, Orduña VA, Declara IM, Martínez EA, Salas NR, Torres E, Lavín DC, Alonso RMR, Falcó E, Oliva JC, Cirera L

Título: Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study

Revista: CANCERS

DOI: 10.3390/cancers15184603

IF: 5,2

Pericay C, Montes AF, Orduña VA, Declara IM, Martínez EA, Salas NR, Torres E, Lavín DC, Alonso RMR, Falcó E, Oliva JC, Cirera L. Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study. CANCERS. 2023. DOI: 10.3390/cancers15184603. IF: 5,2 Q2 D3

Autores/as: Mendez-Vidal MJ, Quintela ML, Lainez-Milagro N, Perez-Valderrama B, Rodriguez CS, Arija JAA, Fernandez IP, Diaz EG, Sorrosal JL, Gonzalez-del-Alba A

Título: SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-023-03276-5

IF: 3,4

Mendez-Vidal MJ, Quintela ML, Lainez-Milagro N, Perez-Valderrama B, Rodriguez CS, Arija JAA, Fernandez IP, Diaz EG, Sorrosal JL, Gonzalez-del-Alba A. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022). CLINICAL & TRANSLATIONAL ONCOLOGY. 2023. 2732-2748. DOI: 10.1007/s12094-023-03276-5. IF: 3,4 Q3 D

Autores/as: de la Pena FA, Novoa SA, Gregori JG, Cortijo LG, Carrasco FH, Martinez MTM, Estevez CM, Stradella A, Losada MJV, Ciruelos E

Título: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-023-03215-4

IF: 3,4

de la Pena FA, Novoa SA, Gregori JG, Cortijo LG, Carrasco FH, Martinez MTM, Estevez CM, Stradella A, Losada MJV, Ciruelos E. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). CLINICAL & TRANSLATIONAL ONCOLOGY. 2023. 2647-2664. DOI: 10.1007/s12094-023-03215-4. IF: 3,4 Q3 D

Autores/as: Montes AF, Alonso V, Aranda E, Elez E, Alfonso PG, Gravalos C, Maurel J, Vera R, Vidal R, Aparicio J

Título: SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-023-03199-1

IF: 3,4

Montes AF, Alonso V, Aranda E, Elez E, Alfonso PG, Gravalos C, Maurel J, Vera R, Vidal R, Aparicio J. SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022). CLINICAL & TRANSLATIONAL ONCOLOGY. 2023. 2718-2731. DOI: 10.1007/s12094-023-03199-1. IF: 3,4 Q3 D

Autores/as: Guil-Luna S, Sanchez-Montero MT, Rodríguez-Ariza A

Título: S-Nitrosylation at the intersection of metabolism and autophagy: Implications for cancer

Revista: BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

DOI: 10.1016/j.bbcan.2023.189012

IF: 11,2

Guil-Luna S, Sanchez-Montero MT, Rodríguez-Ariza A. S-Nitrosylation at the intersection of metabolism and autophagy: Implications for cancer. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. 2023. DOI: 10.1016/j.bbcan.2023.189012. IF: 11,2 Q1 D1

Autores/as: Montes AF, Orduña VA, Martínez EA, Salas NR, Torres E, Lavín DC, Alonso RMR, Falcó E, Oliva JC, Cirera L, Gómez JG, Pericay C

Título: The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer

Revista: ONCOLOGIST

DOI: 10.1093/oncolo/oyad117

IF: 5,8

Montes AF, Orduña VA, Martínez EA, Salas NR, Torres E, Lavín DC, Alonso RMR, Falcó E, Oliva JC, Cirera L, Gómez JG, Pericay C. The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer. ONCOLOGIST. 2023. e902-e909. DOI: 10.1093/oncolo/oyad117. IF: 5,8 Q1 D3

Autores/as: Perez-Garcia JM, Batista MV, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigos L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernandez-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortes J, Braga S

Título: Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

Revista: NEURO-ONCOLOGY

DOI: 10.1093/neuonc/noac144

IF: 15,9

Perez-Garcia JM, Batista MV, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigos L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernandez-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortes J, Braga S. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. NEURO-ONCOLOGY. 2023. 157-166. DOI: 10.1093/neuonc/noac144. IF: 15,9 Q1 D1

Autores/as: Asleh K, Lluch A, Goytain A, Barrios C, Wang XQ, Torrecillas L, Gao DX, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano A, Garcia-Saenz JA, Cejalvo JM, Herranz J, Torres R, de la Haba-rodriguez J, Ayala F, Gomez H, Rojo F, Nielsen TO, Martin M

Título: Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Revista: CLINICAL CANCER RESEARCH

DOI: 10.1158/1078-0432.CCR-22-2191

IF: 11,5

Asleh K, Lluch A, Goytain A, Barrios C, Wang XQ, Torrecillas L, Gao DX, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano A, Garcia-Saenz JA, Cejalvo JM, Herranz J, Torres R, de la Haba-rodriguez J, Ayala F, Gomez H, Rojo F, Nielsen TO, Martin M. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine. CLINICAL CANCER RESEARCH. 2023. 389-400. DOI: 10.1158/1078-0432.CCR-22-2191. IF: 11,5 Q1 D1

Autores/as: Publicaciones in 2022

Publicaciones in 2022

Autores/as: Lara-Chica M, Correa-Saez A, Jimenez-Izquierdo R, Garrido-Rodriguez M, Ponce FJ, Moreno R, Morrison K, Di Vona C, Arato K, Jimenez-Jimenez C, Morrugares R, Schmitz ML, de la Luna S, de la Vega L, Calzado MA

Título: CELL DEATH AND DIFFERENTIATION

Revista: 2022

DOI: 10.1038/s41418-021-00845-5

Lara-Chica M, Correa-Saez A, Jimenez-Izquierdo R, Garrido-Rodriguez M, Ponce FJ, Moreno R, Morrison K, Di Vona C, Arato K, Jimenez-Jimenez C, Morrugares R, Schmitz ML, de la Luna S, de la Vega L, Calzado MA. CELL DEATH AND DIFFERENTIATION. 2022. DOI: 10.1038/s41418-021-00845-5

Autores/as: Climent MA, Font A, Duran I, Puente J, Mendez-Vidal MJ, Saez MI, Lobera CS, Arija JAA, Gonzalez-Del-Alba A, Sanchez-Hernandez A, Fita MJJ, Esteban E, Alonso-Gordoa T, Gonzalez BM, Maroto P, Lazaro-Quintela M, Cassinello-Espinosa J, Perez-Valderrama B, Garcias C, Castellano D

Título: EUROPEAN JOURNAL OF CANCER

Revista: 2022

DOI: 10.1016/j.ejca.2022.08.002

Climent MA, Font A, Duran I, Puente J, Mendez-Vidal MJ, Saez MI, Lobera CS, Arija JAA, Gonzalez-Del-Alba A, Sanchez-Hernandez A, Fita MJJ, Esteban E, Alonso-Gordoa T, Gonzalez BM, Maroto P, Lazaro-Quintela M, Cassinello-Espinosa J, Perez-Valderrama B, Garcias C, Castellano D. EUROPEAN JOURNAL OF CANCER. 2022. DOI: 10.1016/j.ejca.2022.08.002

Autores/as: Argiles G, Mulet N, Valladares-Ayerbes M, Vieitez JM, Gravalos C, Garcia-Alfonso P, Santos C, Tobena M, Garcia-Paredes B, Benavides M, Cano MT, Loupakis F, Rodriguez-Garrote M, Rivera F, Goldberg RM, Cremolini C, Bennouna J, Ciardiello F, Tabernero JM, Aranda E, Tabernero J

Título: EUROPEAN JOURNAL OF CANCER

Revista: 2022

DOI: 10.1016/j.ejca.2022.09.037

Argiles G, Mulet N, Valladares-Ayerbes M, Vieitez JM, Gravalos C, Garcia-Alfonso P, Santos C, Tobena M, Garcia-Paredes B, Benavides M, Cano MT, Loupakis F, Rodriguez-Garrote M, Rivera F, Goldberg RM, Cremolini C, Bennouna J, Ciardiello F, Tabernero JM, Aranda E, Tabernero J. EUROPEAN JOURNAL OF CANCER. 2022. DOI: 10.1016/j.ejca.2022.09.037

Autores/as: Garcia-Torres F, Jablonski MJ, Gomez-Solis A, Moriana JA, Jaen-Moreno M, Moreno-Diaz MJ, Aranda E

Título: HEALTH PSYCHOLOGY REPORT

Revista: 2022

DOI: 10.5114/hpr.2021.111297

Garcia-Torres F, Jablonski MJ, Gomez-Solis A, Moriana JA, Jaen-Moreno M, Moreno-Diaz MJ, Aranda E. HEALTH PSYCHOLOGY REPORT. 2022. DOI: 10.5114/hpr.2021.111297

Autores/as: Calvo-Lopez T, Paz-Cabezas M, Llovet P, Ibanez MD, Sastre J, Alonso-Orduna V, Vieitez JM, Yubero A, Vera R, Asensio-Martinez E, Garcia-Alfonso P, Aranda E, Diaz-Rubio E, Perez-Villamil B

Título: CANCER BIOMARKERS

Revista: 2022

DOI: 10.3233/CBM-210353

Calvo-Lopez T, Paz-Cabezas M, Llovet P, Ibanez MD, Sastre J, Alonso-Orduna V, Vieitez JM, Yubero A, Vera R, Asensio-Martinez E, Garcia-Alfonso P, Aranda E, Diaz-Rubio E, Perez-Villamil B. CANCER BIOMARKERS. 2022. DOI: 10.3233/CBM-210353

Autores/as: Ortiz-Morales MJ, Toledano-Fonseca M, Mena-Osuna R, Cano MT, Gomez-Espana A, De la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E

Título: CANCERS

Revista: 2022

DOI: 10.3390/cancers14133054

Ortiz-Morales MJ, Toledano-Fonseca M, Mena-Osuna R, Cano MT, Gomez-Espana A, De la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E. CANCERS. 2022. DOI: 10.3390/cancers14133054

Autores/as: Herrera-Martinez Y, Gonzalez MJC, Pedraza-Arevalo S, Martinez MDG, Martinez AR, Menchen AG, Molina MAB, Galvez-Moreno MA, Moreno-Vega AL, Luque RM, Herrera-Martinez AD

Título: FRONTIERS IN ENDOCRINOLOGY

Revista: 2022

DOI: 10.3389/fendo.2021.812385

Herrera-Martinez Y, Gonzalez MJC, Pedraza-Arevalo S, Martinez MDG, Martinez AR, Menchen AG, Molina MAB, Galvez-Moreno MA, Moreno-Vega AL, Luque RM, Herrera-Martinez AD. FRONTIERS IN ENDOCRINOLOGY. 2022. DOI: 10.3389/fendo.2021.812385

Autores/as: Pinto A, Reig O, Iglesias C, Gallardo E, Garcia-del Muro X, Alonso T, Anguera G, Suarez C, Munoz-Langa J, Villalobos-Leon L, Rodriguez-Sanchez A, Lainez N, Martinez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzman JC, Mendez-Vidal MJ, Rubio G, Garcia I, Capdevila L, Lambea J, Vazquez S, Fernandez O, Hernando-Polo S, Cerezo S, Santander C, Garcia-Marrero R, Zambrana F, Gonzalez-del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, Garcia A, Sotelo M, Arevalo MG, Garcia-Donas J, Hernandez C, Bolos MV, Llinares J, Climent MA

Título: CLINICAL GENITOURINARY CANCER

Revista: 2022

DOI: 10.1016/j.clgc.2021.09.006

Pinto A, Reig O, Iglesias C, Gallardo E, Garcia-del Muro X, Alonso T, Anguera G, Suarez C, Munoz-Langa J, Villalobos-Leon L, Rodriguez-Sanchez A, Lainez N, Martinez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzman JC, Mendez-Vidal MJ, Rubio G, Garcia I, Capdevila L, Lambea J, Vazquez S, Fernandez O, Hernando-Polo S, Cerezo S, Santander C, Garcia-Marrero R, Zambrana F, Gonzalez-del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, Garcia A, Sotelo M, Arevalo MG, Garcia-Donas J, Hernandez C, Bolos MV, Llinares J, Climent MA. CLINICAL GENITOURINARY CANCER. 2022. DOI: 10.1016/j.clgc.2021.09.006

Autores/as: Elez E, Gomez-Espana MA, Gravalos C, Garcia-Alfonso P, Ortiz-Morales MJ, Losa F, Diaz IA, Grana B, Toledano-Fonseca M, Valladares-Ayerbes M, Polo E, Salgado M, De Castro EM, Safont MJ, Salud A, Ruiz-Casado A, Tabernero J, Riesco MD, Rodriguez-Ariza A, Aranda E

Título: BRITISH JOURNAL OF CANCER

Revista: 2022

DOI: 10.1038/s41416-021-01638-w

Elez E, Gomez-Espana MA, Gravalos C, Garcia-Alfonso P, Ortiz-Morales MJ, Losa F, Diaz IA, Grana B, Toledano-Fonseca M, Valladares-Ayerbes M, Polo E, Salgado M, De Castro EM, Safont MJ, Salud A, Ruiz-Casado A, Tabernero J, Riesco MD, Rodriguez-Ariza A, Aranda E. BRITISH JOURNAL OF CANCER. 2022. DOI: 10.1038/s41416-021-01638-w

Autores/as: Garcia-Torres F, Tejero-Perea A, Gomez-Solis A, Castillo-Mayen R, Jaen-Moreno MJ, Luque B, Galvez-Lara M, Sanchez-Raya A, Jablonski M, Rodriguez-Alonso B, Aranda E

Título: TRIALS

Revista: 2022

DOI: 10.1186/s13063-022-06731-w

Garcia-Torres F, Tejero-Perea A, Gomez-Solis A, Castillo-Mayen R, Jaen-Moreno MJ, Luque B, Galvez-Lara M, Sanchez-Raya A, Jablonski M, Rodriguez-Alonso B, Aranda E. TRIALS. 2022. DOI: 10.1186/s13063-022-06731-w

Autores/as: Garcia-Torres F, Gomez-Solis A, Garcia SR, Castillo-Mayen R, Ruiz-Ruano VG, Moreno E, Moriana JA, Luque-Salas B, Jaen-Moreno MJ, Cuadrado-Hidalgo F, Galvez-Lara M, Jablonski M, Rodriguez-Alonso B, Aranda E

Título: FRONTIERS IN PSYCHOLOGY

Revista: 2022

DOI: 10.3389/fpsyg.2022.871929

Garcia-Torres F, Gomez-Solis A, Garcia SR, Castillo-Mayen R, Ruiz-Ruano VG, Moreno E, Moriana JA, Luque-Salas B, Jaen-Moreno MJ, Cuadrado-Hidalgo F, Galvez-Lara M, Jablonski M, Rodriguez-Alonso B, Aranda E. FRONTIERS IN PSYCHOLOGY. 2022. DOI: 10.3389/fpsyg.2022.871929

Autores/as: Pedraza-Arevalo S, Ibanez-Costa A, Blazquez-Encinas R, Branco MR, Vazquez-Borrego MC, Herrera-Martinez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sanchez A, Galvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castano JP

Título: MOLECULAR ONCOLOGY

Revista: 2022

DOI: 10.1002/1878-0261.13107

Pedraza-Arevalo S, Ibanez-Costa A, Blazquez-Encinas R, Branco MR, Vazquez-Borrego MC, Herrera-Martinez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sanchez A, Galvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castano JP. MOLECULAR ONCOLOGY. 2022. DOI: 10.1002/1878-0261.13107

Autores/as: Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, Tyson C, Stanoeva D, Daelemans S, Rombouts M, Mariathasan S, Tea JS, Mousa K, Sharma S, Aleshin A, Banchereau R, Castellano D, Powles T

Título: EUROPEAN UROLOGY

Revista: 2022

DOI: 10.1016/j.eururo.2022.04.013

Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, Tyson C, Stanoeva D, Daelemans S, Rombouts M, Mariathasan S, Tea JS, Mousa K, Sharma S, Aleshin A, Banchereau R, Castellano D, Powles T. EUROPEAN UROLOGY. 2022. DOI: 10.1016/j.eururo.2022.04.013

Autores/as: Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang JY, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D

Título: LANCET ONCOLOGY

Revista: 2022

DOI: 10.1016/S1470-2045(22)00212-1

Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang JY, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. LANCET ONCOLOGY. 2022. DOI: 10.1016/S1470-2045(22)00212-1

Autores/as: Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini R, He CS, Mody K, Cella D

Título: ONKOUROLOGIYA

Revista: 2022

DOI: 10.17650/1726-9776-2022-18-2-39-57

Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini R, He CS, Mody K, Cella D. ONKOUROLOGIYA. 2022. DOI: 10.17650/1726-9776-2022-18-2-39-57

Autores/as: Porta VG, Camps C, Duran MAC, Gallardo E, del Alba AG, Lazaro-Quintela M, Vidal MJM, Marin AP, Puente J, Anton-Rodriguez C, Caballero-Martinez F, Campos-Lucas FJ, Lugo I, Rogado A, Duran I

Título: CLINICAL & TRANSLATIONAL ONCOLOGY

Revista: 2022

DOI: 10.1007/s12094-021-02703-9

Porta VG, Camps C, Duran MAC, Gallardo E, del Alba AG, Lazaro-Quintela M, Vidal MJM, Marin AP, Puente J, Anton-Rodriguez C, Caballero-Martinez F, Campos-Lucas FJ, Lugo I, Rogado A, Duran I. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022. DOI: 10.1007/s12094-021-02703-9

Autores/as: Gil-Guillen VF, Balsa A, Bernardez B, Llorca CVY, Marquez-Contreras E, de la Haba-Rodriguez J, Castellano JM, Gomez-Martinez J

Título: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH

Revista: 2022

DOI: 10.3390/ijerph191912036

Gil-Guillen VF, Balsa A, Bernardez B, Llorca CVY, Marquez-Contreras E, de la Haba-Rodriguez J, Castellano JM, Gomez-Martinez J. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2022. DOI: 10.3390/ijerph191912036

Autores/as: Montes AF, Elez E, Vivancos A, Martinez N, Gonzalez P, Covela M, de la Camara J, Cousillas A, Mendez JC, Grana B, Aranda E

Título: CLINICAL & TRANSLATIONAL ONCOLOGY

Revista: 2022

DOI: 10.1007/s12094-021-02767-7

Montes AF, Elez E, Vivancos A, Martinez N, Gonzalez P, Covela M, de la Camara J, Cousillas A, Mendez JC, Grana B, Aranda E. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022. DOI: 10.1007/s12094-021-02767-7

Autores/as: Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Csoszi T, Anton A, Turner N, Casas MI, Morales S, Alba E, Calvo L, De La Haba-Rodriguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sanchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M

Título: EUROPEAN JOURNAL OF CANCER

Revista: 2022

DOI: 10.1016/j.ejca.2022.03.006

Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Csoszi T, Anton A, Turner N, Casas MI, Morales S, Alba E, Calvo L, De La Haba-Rodriguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sanchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M. EUROPEAN JOURNAL OF CANCER. 2022. DOI: 10.1016/j.ejca.2022.03.006

Autores/as: Albanell J, Perez-Garcia JM, Gil-Gil M, Curigliano G, Ruiz-Borrego M, Comerma L, Gibert J, Bellet M, Bermejo B, Calvo L, de la Haba J, Espinosa E, Minisini AM, Quiroga V, Bertran AS, Mina L, Bellosillo B, Rojo F, Menendez S, Sampayo-Cordero M, Popa C, Malfettone A, Cortes J, Llombart-Cussac A

Título: CLINICAL CANCER RESEARCH

Revista: 2022

DOI: 10.1158/1078-0432.CCR-22-1281

Albanell J, Perez-Garcia JM, Gil-Gil M, Curigliano G, Ruiz-Borrego M, Comerma L, Gibert J, Bellet M, Bermejo B, Calvo L, de la Haba J, Espinosa E, Minisini AM, Quiroga V, Bertran AS, Mina L, Bellosillo B, Rojo F, Menendez S, Sampayo-Cordero M, Popa C, Malfettone A, Cortes J, Llombart-Cussac A. CLINICAL CANCER RESEARCH. 2022. DOI: 10.1158/1078-0432.CCR-22-1281

Autores/as: Albanell J, Martinez MT, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martinez-Janez N, Moreno F, Fernandez I, Alarcon J, Virizuela JA, de la Haba-Rodriguez J, Sanchez-Rovira P, Gonzalez-Cortijo L, Margeli M, Sanchez-Munoz A, Anton A, Casas M, Bezares S, Rojo F

Título: EUROPEAN JOURNAL OF CANCER

Revista: 2022

DOI: 10.1016/j.ejca.2021.11.010

Albanell J, Martinez MT, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martinez-Janez N, Moreno F, Fernandez I, Alarcon J, Virizuela JA, de la Haba-Rodriguez J, Sanchez-Rovira P, Gonzalez-Cortijo L, Margeli M, Sanchez-Munoz A, Anton A, Casas M, Bezares S, Rojo F. EUROPEAN JOURNAL OF CANCER. 2022. DOI: 10.1016/j.ejca.2021.11.010

Autores/as: Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, Garcia-Donas J, Rodriguez MG, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuellar-Rivas MA, Rodriguez-Alonso RM, Rodriguez-Moreno JF, Suarez-Rodriguez C

Título: ESMO OPEN

Revista: 2022

DOI: 10.1016/j.esmoop.2022.100463

Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, Garcia-Donas J, Rodriguez MG, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuellar-Rivas MA, Rodriguez-Alonso RM, Rodriguez-Moreno JF, Suarez-Rodriguez C. ESMO OPEN. 2022. DOI: 10.1016/j.esmoop.2022.100463

Autores/as: Bofill JS, Anton FM, Sanchez CAR, Calvo EG, Melia CH, Gil EMC, Vidal M, Jimenez-Rodriguez B, Merino LD, Janez NM, Vazquez RV, Salas RD, Torres AA, Lopez IMA, Gregori JG, Garcia VQ, Rubio EV, De la Haba-Rodriguez J, Gonzalez-Santiago S, Fernandez ND, Molins AB, De Ibarguen BCS, Mingorance JID, Ezquerra MB, De Casa S, Gimeno A, Martin M

Título: BREAST

Revista: 2022

DOI: 10.1016/j.breast.2022.09.006

Bofill JS, Anton FM, Sanchez CAR, Calvo EG, Melia CH, Gil EMC, Vidal M, Jimenez-Rodriguez B, Merino LD, Janez NM, Vazquez RV, Salas RD, Torres AA, Lopez IMA, Gregori JG, Garcia VQ, Rubio EV, De la Haba-Rodriguez J, Gonzalez-Santiago S, Fernandez ND, Molins AB, De Ibarguen BCS, Mingorance JID, Ezquerra MB, De Casa S, Gimeno A, Martin M. BREAST. 2022. DOI: 10.1016/j.breast.2022.09.006

Autores/as: Herrera-Martinez Y, Teomiro CA, Idougourram SL, Puertas MJM, Continente AC, Blanch RS, Castano JP, Moreno MAG, Gahete MD, Luque RM, Herrera-Martinez AD

Título: CANCERS

Revista: 2022

DOI: 10.3390/cancers14010111

Herrera-Martinez Y, Teomiro CA, Idougourram SL, Puertas MJM, Continente AC, Blanch RS, Castano JP, Moreno MAG, Gahete MD, Luque RM, Herrera-Martinez AD. CANCERS. 2022. DOI: 10.3390/cancers14010111

Autores/as: Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J

Título: CLINICAL & TRANSLATIONAL ONCOLOGY

Revista: 2022

DOI: 10.1007/s12094-022-02816-9

Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022. DOI: 10.1007/s12094-022-02816-9

Autores/as: de la Haba-Rodriguez J, Lloret FF, Salgado MAV, Arce MO, Gutierrez AC, Jimenez JGD, Zambrano CB, Alonso RMR, Lopez RL, Salas NR

Título: CLINICAL & TRANSLATIONAL ONCOLOGY

Revista: 2022

DOI: 10.1007/s12094-022-02817-8

de la Haba-Rodriguez J, Lloret FF, Salgado MAV, Arce MO, Gutierrez AC, Jimenez JGD, Zambrano CB, Alonso RMR, Lopez RL, Salas NR. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022. DOI: 10.1007/s12094-022-02817-8

Autores/as: Perez-de-Villar J, Arjona-Sanchez A, Rufian-Andujar B, Valenzuela-Molina F, Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Casado-Adam A, Viyuela-Garcia C, Rufian-Pena S, Caro-Cuenca T, Moreno-Vega A, Briceno-Delgado J

Título: CIRUGIA ESPANOLA

Revista: 2022

DOI: 10.1016/j.ciresp.2021.05.001

Perez-de-Villar J, Arjona-Sanchez A, Rufian-Andujar B, Valenzuela-Molina F, Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Casado-Adam A, Viyuela-Garcia C, Rufian-Pena S, Caro-Cuenca T, Moreno-Vega A, Briceno-Delgado J. CIRUGIA ESPANOLA. 2022. DOI: 10.1016/j.ciresp.2021.05.001

Autores/as: Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E

Título: MOLECULAR ONCOLOGY

Revista: 2022

DOI: 10.1002/1878-0261.13141

Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. MOLECULAR ONCOLOGY. 2022. DOI: 10.1002/1878-0261.13141

Autores/as: Ciria R, Ayllon MD, Padial A, Gomez-Serrano J, Garcia-Gaitan C, Gomez-Espana A, Espejo JJ, Briceno J

Título: ANNALS OF SURGICAL ONCOLOGY

Revista: 2022

DOI: 10.1245/s10434-021-11005-x

Ciria R, Ayllon MD, Padial A, Gomez-Serrano J, Garcia-Gaitan C, Gomez-Espana A, Espejo JJ, Briceno J. ANNALS OF SURGICAL ONCOLOGY. 2022. DOI: 10.1245/s10434-021-11005-x

Autores/as: Casarrubios M, Provencio M, Nadal E, Insa A, Garcia-Campelo MD, Lazaro-Quintela M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Bernabe R, Vinolas N, Aranda IB, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernandez-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermudez A

Título: JOURNAL FOR IMMUNOTHERAPY OF CANCER

Revista: 2022

DOI: 10.1136/jitc-2022-005320

Casarrubios M, Provencio M, Nadal E, Insa A, Garcia-Campelo MD, Lazaro-Quintela M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Bernabe R, Vinolas N, Aranda IB, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernandez-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermudez A. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022. DOI: 10.1136/jitc-2022-005320

Autores/as: Benavides M, Gomez-Espana A, Garcia-Alfonso P, Gonzalez CG, Vieitez JM, Rivera F, Safont MJ, Abad A, Sastre J, Valladares-Ayerbes M, Carrato A, Gonzalez-Flores E, Robles L, Salud A, Alonso-Orduna V, Montagut C, Asensio E, Diaz-Rubio E, Aranda E

Título: EJSO

Revista: 2022

DOI: 10.1016/j.ejso.2021.11.122

Benavides M, Gomez-Espana A, Garcia-Alfonso P, Gonzalez CG, Vieitez JM, Rivera F, Safont MJ, Abad A, Sastre J, Valladares-Ayerbes M, Carrato A, Gonzalez-Flores E, Robles L, Salud A, Alonso-Orduna V, Montagut C, Asensio E, Diaz-Rubio E, Aranda E. EJSO. 2022. DOI: 10.1016/j.ejso.2021.11.122

Autores/as: Garcia-Ortiz MV, De La Torre-Aguilar MJ, Morales-Ruiz T, Gomez-Fernandez A, Flores-Rojas K, Gil-Campos M, Martin-Borreguero P, Ariza RR, Roldan-Arjona T, Perez-Navero JL

Título: Analysis of Global and Local DNA Methylation Patterns in Blood Samples of Patients With Autism Spectrum Disorder

Revista: FRONTIERS IN PEDIATRICS

DOI: 10.3389/fped.202685310

Garcia-Ortiz MV, De La Torre-Aguilar MJ, Morales-Ruiz T, Gomez-Fernandez A, Flores-Rojas K, Gil-Campos M, Martin-Borreguero P, Ariza RR, Roldan-Arjona T, Perez-Navero JL. Analysis of Global and Local DNA Methylation Patterns in Blood Samples of Patients With Autism Spectrum Disorder. FRONTIERS IN PEDIATRICS. 202 9():-. DOI: 10.3389/fped.202685310.

Autores/as: IF: 3,418 Q1 D2

IF: 3,418

IF: 3,418 Q1 D2

Autores/as: Perez-Sanchez C, Barbarroja N, Pantaleao LC, Lopez-Sanchez LM, Ozanne SE, Jurado-Gamez B, Aranda E, Lopez-Pedrera C, Rodriguez-Ariza A

Título: Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer

Revista: JOURNAL OF PERSONALIZED MEDICINE

DOI: 10.3390/jpm11020111

Perez-Sanchez C, Barbarroja N, Pantaleao LC, Lopez-Sanchez LM, Ozanne SE, Jurado-Gamez B, Aranda E, Lopez-Pedrera C, Rodriguez-Ariza A. Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer. JOURNAL OF PERSONALIZED MEDICINE. 2021. 11(2):-. DOI: 10.3390/jpm11020111.

Autores/as: IF: 4,945 Q1 D2

IF: 4,945

IF: 4,945 Q1 D2

Autores/as: Vera R, Salgado M, Safont MJ, Gallego J, Gonzalez E, Elez E, Aranda E

Título: Controversies in the treatment of RAS wild-type metastatic colorectal cancer

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-020-02475-8

Vera R, Salgado M, Safont MJ, Gallego J, Gonzalez E, Elez E, Aranda E. Controversies in the treatment of RAS wild-type metastatic colorectal cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(4):827-839. DOI: 10.1007/s12094-020-02475-8.

Autores/as: IF: 3,405 Q3

IF: 3,405

IF: 3,405 Q3

Autores/as: Garcia-Alfonso P, Munoz A, Jimenez-Castro J, Jimenez-Fonseca P, Pericay C, Longo-Munoz F, Reyna-Fortes C, Argiles-Martinez G, Gonzalez-Astorga B, Gomez-Reina MJ, Ruiz-Casado A, Rodriguez-Salas N, Lopez-Lopez R, Carmona-Bayonas A, Conde-Herrero V, Aranda E

Título: Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study

Revista: CANCERS

DOI: 10.3390/cancers1318451

Garcia-Alfonso P, Munoz A, Jimenez-Castro J, Jimenez-Fonseca P, Pericay C, Longo-Munoz F, Reyna-Fortes C, Argiles-Martinez G, Gonzalez-Astorga B, Gomez-Reina MJ, Ruiz-Casado A, Rodriguez-Salas N, Lopez-Lopez R, Carmona-Bayonas A, Conde-Herrero V, Aranda E. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. CANCERS. 2021. 13(18):-. DOI: 10.3390/cancers1318451

Autores/as: IF: 6,639 Q1 D3

IF: 6,639

IF: 6,639 Q1 D3

Autores/as: Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales MJ, Mozo JLM, Munoz A, Duran G, Sastre J, Safont MJ, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez JM, Yubero A, Aranda E

Título: First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

Revista: DRUGS & AGING

DOI: 10.1007/s40266-021-00834-w

Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales MJ, Mozo JLM, Munoz A, Duran G, Sastre J, Safont MJ, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez JM, Yubero A, Aranda E. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. DRUGS & AGING. 2021. 38(3):219-231. DOI: 10.1007/s40266-021-00834-w.

Autores/as: IF: 3,923 Q2 D5

IF: 3,923

IF: 3,923 Q2 D5

Autores/as: Guil-Luna S, Sedlik C, Piaggio E

Título: Humanized Mouse Models to Evaluate Cancer Immunotherapeutics

Revista: ANNUAL REVIEW OF CANCER BIOLOGY, VOL 5, 2021

DOI: 10.1146/annurev-cancerbio-050520-100526

Guil-Luna S, Sedlik C, Piaggio E. Humanized Mouse Models to Evaluate Cancer Immunotherapeutics. ANNUAL REVIEW OF CANCER BIOLOGY, VOL 5, 2021. 2021. 5():119-13 DOI: 10.1146/annurev-cancerbio-050520-100526.

Autores/as: IF: 9,391 Q1 D2

IF: 9,391

IF: 9,391 Q1 D2

Autores/as: Manzanares-Martin B, Aranda AC, del Puerto-Nevado L, Gonzalez R, Solanes S, Gomez-Espana MA, Garcia-Foncillas J, Aranda E

Título: Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes

Revista: JOURNAL FOR IMMUNOTHERAPY OF CANCER

DOI: 10.1136/jitc-2020-001705

Manzanares-Martin B, Aranda AC, del Puerto-Nevado L, Gonzalez R, Solanes S, Gomez-Espana MA, Garcia-Foncillas J, Aranda E. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021. 9(4):-. DOI: 10.1136/jitc-2020-001705.

Autores/as: IF: 13,751 Q1 D1

IF: 13,751

IF: 13,751 Q1 D1

Autores/as: Lopez-Sanchez LM, Mena R, Guil-Luna S, Mantrana A, Penarando J, Toledano-Fonseca M, Conde F, De La Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A

Título: Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells

Revista: LABORATORY INVESTIGATION

DOI: 10.1038/s41374-020-00507-z

Lopez-Sanchez LM, Mena R, Guil-Luna S, Mantrana A, Penarando J, Toledano-Fonseca M, Conde F, De La Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells. LABORATORY INVESTIGATION. 2021. 101(3):292-303. DOI: 10.1038/s41374-020-00507-z.

Autores/as: IF: 5,662 Q1 D2

IF: 5,662

IF: 5,662 Q1 D2

Autores/as: Gomez-Espana MA, Montes AF, Garcia-Carbonero R, Mercade TM, Maurel J, Martin AM, Pazo-Cid R, Vera R, Carrato A, Feliu J

Título: SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-021-02573-1

Gomez-Espana MA, Montes AF, Garcia-Carbonero R, Mercade TM, Maurel J, Martin AM, Pazo-Cid R, Vera R, Carrato A, Feliu J. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(5):988-1000. DOI: 10.1007/s12094-021-02573-1.

Autores/as: IF: 3,405 Q3 D

IF: 3,405

IF: 3,405 Q3 D

Autores/as: Toledano-Fonseca M, Cano MT, Inga E, Gomez-Espana A, Guil-Luna S, Garcia-Ortiz MV, Mena-Osuna R, De la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E

Título: The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer

Revista: CANCERS

DOI: 3390/cancers13061210

Toledano-Fonseca M, Cano MT, Inga E, Gomez-Espana A, Guil-Luna S, Garcia-Ortiz MV, Mena-Osuna R, De la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E. The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer. CANCERS. 2021. 13(6):-. DOI: 3390/cancers13061210.

Autores/as: IF: 6,639 Q1 D3

IF: 6,639

IF: 6,639 Q1 D3

Autores/as: Garcia-Carmona M, Garcia-Torres F, Jablonski MJ, Solis AG, Jaen-Moreno MJ, Moriana JA, Moreno-Diaz MJ, Aranda E

Título: The influence of family social support on quality of life of informal caregivers of cancer patients

Revista: NURSING OPEN

DOI: 10.1002/nop2.887

Garcia-Carmona M, Garcia-Torres F, Jablonski MJ, Solis AG, Jaen-Moreno MJ, Moriana JA, Moreno-Diaz MJ, Aranda E. The influence of family social support on quality of life of informal caregivers of cancer patients. NURSING OPEN. 2021. 8(6):3411-3419. DOI: 10.1002/nop2.887.

Autores/as: IF: 1,762 Q3

IF: 1,762

IF: 1,762 Q3

Autores/as: Alors-Perez E, Blazquez-Encinas R, Alcala S, Viyuela-Garcia C, Pedraza-Arevalo S, Herrero-Aguayo V, Jimenez-Vacas JM, Mafficini A, Sanchez-Frias ME, Cano MT, Abollo-Jimenez F, Marin-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sanchez L, Sanchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sanchez A, Ibanez-Costa A, Sainz B, Luque RM, Castano JP

Título: Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

Revista: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

DOI: 10.1186/s13046-021-02153-9

Alors-Perez E, Blazquez-Encinas R, Alcala S, Viyuela-Garcia C, Pedraza-Arevalo S, Herrero-Aguayo V, Jimenez-Vacas JM, Mafficini A, Sanchez-Frias ME, Cano MT, Abollo-Jimenez F, Marin-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sanchez L, Sanchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sanchez A, Ibanez-Costa A, Sainz B, Luque RM, Castano JP. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 202 40(1):-. DOI: 10.1186/s13046-021-02153-9.

Autores/as: IF: 11,161 Q1 D1

IF: 11,161

IF: 11,161 Q1 D1

Autores/as: Sastre J, Garcia-Alfonso P, Vieitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Diaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martinez E, Garcia-Paredes B, Lopez RL, Guillot M, Valladares-Ayerbes M, Aranda E, Diaz-Rubio E

Título: Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and < 3 baseline circulating tumour cells: the randomised phase II VISNU-2 study

Revista: ESMO OPEN

DOI: 10.1016/j.esmoop.2021.10006

Sastre J, Garcia-Alfonso P, Vieitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Diaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martinez E, Garcia-Paredes B, Lopez RL, Guillot M, Valladares-Ayerbes M, Aranda E, Diaz-Rubio E. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and < 3 baseline circulating tumour cells: the randomised phase II VISNU-2 study. ESMO OPEN. 2021. 6(2):-. DOI: 10.1016/j.esmoop.2021.10006

Autores/as: IF: 6,54 Q1 D3

IF: 6,54

IF: 6,54 Q1 D3

Autores/as: Conde E, Earl J, Crespo-Toro L, Blanco-Agudo C, Ramos-Munoz E, Rodriguez-Serrano EM, Avila JCM, Salinas-Munoz L, Serrano-Huertas S, Ferreiro R, Rodriguez-Garrote M, Sainz B, Massuti B, Alfonso PG, Benavides M, Aranda E, Garcia-Bermejo ML, Carrato A

Título: Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study

Revista: CANCERS

DOI: 10.3390/cancers13071710

Conde E, Earl J, Crespo-Toro L, Blanco-Agudo C, Ramos-Munoz E, Rodriguez-Serrano EM, Avila JCM, Salinas-Munoz L, Serrano-Huertas S, Ferreiro R, Rodriguez-Garrote M, Sainz B, Massuti B, Alfonso PG, Benavides M, Aranda E, Garcia-Bermejo ML, Carrato A. Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. CANCERS. 2021. 13(7):-. DOI: 10.3390/cancers13071710.

Autores/as: IF: 6,639 Q1 D3

IF: 6,639

IF: 6,639 Q1 D3

Autores/as: Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, Garcia-Grande A, Romero A, Franco F, Provencio M

Título: Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

Revista: JOURNAL FOR IMMUNOTHERAPY OF CANCER

DOI: 10.1136/jitc-2021-00280

Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, Garcia-Grande A, Romero A, Franco F, Provencio M. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021. 9(8):-. DOI: 10.1136/jitc-2021-00280

Autores/as: IF: 13,751 Q1 D1

IF: 13,751

IF: 13,751 Q1 D1

Autores/as: Taieb J, Aranda E, Raouf S, Dunn H, Arnold D

Título: Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer

Revista: CLINICAL COLORECTAL CANCER

DOI: 10.1016/j.clcc.2020.10.00

Taieb J, Aranda E, Raouf S, Dunn H, Arnold D. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER. 2021. 20(1):42-51. DOI: 10.1016/j.clcc.2020.10.00

Autores/as: IF: 4,481 Q2 D5

IF: 4,481

IF: 4,481 Q2 D5

Autores/as: Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Aranda IB, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M

Título: Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials

Revista: LUNG CANCER

DOI: 10.1016/j.lungcan.2021.09.002

Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Aranda IB, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. LUNG CANCER. 2021. 161():76-85. DOI: 10.1016/j.lungcan.2021.09.002.

Autores/as: IF: 5,705 Q1 D3

IF: 5,705

IF: 5,705 Q1 D3

Autores/as: Dols MC, Zambrano CB, Gutierrez LC, Sett RC, Lopez-Barajas MIB, Navalon FG, Perez JLF, Bermudez GS, Torres PT, Mingorance ID, Marin AG, Oriol AL, Lario AP, Maurino PS, Gomez OH, Munoz DM, Lopez AJJ, Gonzalez IH, Yague AS, Lopez BS

Título: Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis

Revista: BMJ SUPPORTIVE & PALLIATIVE CARE

DOI: 10.1136/bmjspcare-2020-002249

Dols MC, Zambrano CB, Gutierrez LC, Sett RC, Lopez-Barajas MIB, Navalon FG, Perez JLF, Bermudez GS, Torres PT, Mingorance ID, Marin AG, Oriol AL, Lario AP, Maurino PS, Gomez OH, Munoz DM, Lopez AJJ, Gonzalez IH, Yague AS, Lopez BS. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis. BMJ SUPPORTIVE & PALLIATIVE CARE. 2021. 11(1):25-31. DOI: 10.1136/bmjspcare-2020-002249.

Autores/as: IF: 3,568 Q2 D4

IF: 3,568

IF: 3,568 Q2 D4

Autores/as: Ribelles N, Alvarez-Lopez I, Arcusa A, Chacon JI, de la Haba J, Garcia-Corbacho J, Garcia-Mata J, Jara C, Jerez JM, Lazaro-Quintela M, Leon-Mateos L, Ramirez-Merino N, Tibau A, Garcia-Palomo A

Título: Electronic health records and patient registries in medical oncology departments in Spain

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-021-02614-9

Ribelles N, Alvarez-Lopez I, Arcusa A, Chacon JI, de la Haba J, Garcia-Corbacho J, Garcia-Mata J, Jara C, Jerez JM, Lazaro-Quintela M, Leon-Mateos L, Ramirez-Merino N, Tibau A, Garcia-Palomo A. Electronic health records and patient registries in medical oncology departments in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(10):2099-210 DOI: 10.1007/s12094-021-02614-9.

Autores/as: IF: 3,405 Q3 D

IF: 3,405

IF: 3,405 Q3 D

Autores/as: Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Kopyltsov E, Mendez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Gordoa TA, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing DY, Choueiri TK

Título: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Revista: NEW ENGLAND JOURNAL OF MEDICINE

DOI: 10.1056/NEJMoa2035716

IF: 91,245

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Kopyltsov E, Mendez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Gordoa TA, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing DY, Choueiri TK. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE. 2021. 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. IF: 91,245 Q1 D1

Autores/as: Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Munoz M, Bermejo B, Margeli M, Anton A, Casas M, Csoszi T, Murillo L, Morales S, Calvo L, Lang I, Alba E, de la Haba-Rodriguez J, Ramos M, Lopez IA, Gal-Yam E, Garcia-Palomo A, Alvarez E, Gonzalez-Santiago S, Rodriguez CA, Servitja S, Corsaro M, Rodrigalvarez G, Zielinski C, Martin M

Título: Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

Revista: EUROPEAN JOURNAL OF CANCER

DOI: 1016/j.ejca.2021.07.004

Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Munoz M, Bermejo B, Margeli M, Anton A, Casas M, Csoszi T, Murillo L, Morales S, Calvo L, Lang I, Alba E, de la Haba-Rodriguez J, Ramos M, Lopez IA, Gal-Yam E, Garcia-Palomo A, Alvarez E, Gonzalez-Santiago S, Rodriguez CA, Servitja S, Corsaro M, Rodrigalvarez G, Zielinski C, Martin M. Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. EUROPEAN JOURNAL OF CANCER. 2021. 156():70-82. DOI: 1016/j.ejca.2021.07.004.

Autores/as: IF: 9,192 Q1 D2

IF: 9,192

IF: 9,192 Q1 D2

Autores/as: Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csoszi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Bartlett CH, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Saenz JA, Chacon JI, Swift C, Thallinger C, Gil-Gil M

Título: Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL

Revista: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2020.12.013

Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csoszi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Bartlett CH, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Saenz JA, Chacon JI, Swift C, Thallinger C, Gil-Gil M. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. ANNALS OF ONCOLOGY. 2021. 32(4):488-499. DOI: 10.1016/j.annonc.2020.12.013.

Autores/as: IF: 32,976 Q1 D1

IF: 32,976

IF: 32,976 Q1 D1

Autores/as: Astorga BG, Ballabrera FS, Aguilar EA, Fernandez EE, Garcia-Alfonso P, Flores EG, Garcia RV, Montes AF, Munoz AML, Salvia AS

Título: Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-021-02568-y

Astorga BG, Ballabrera FS, Aguilar EA, Fernandez EE, Garcia-Alfonso P, Flores EG, Garcia RV, Montes AF, Munoz AML, Salvia AS. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(8):1520-1528. DOI: 10.1007/s12094-021-02568-y.

Autores/as: IF: 3,405 Q3

IF: 3,405

IF: 3,405 Q3

Autores/as: Rivera F, Izquierdo-Manuel M, Garcia-Alfonso P, de Castro EM, Gallego J, Limon ML, Alsina M, Lopez L, Galan M, Falco E, Manzano JL, Gonzalez E, Munoz-Unceta N, Lopez C, Aranda E, Fernandez E, Jorge M, Jimenez-Fonseca P

Título: Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

Revista: EUROPEAN JOURNAL OF CANCER

DOI: 10.1016/j.ejca.2020.12.005

Rivera F, Izquierdo-Manuel M, Garcia-Alfonso P, de Castro EM, Gallego J, Limon ML, Alsina M, Lopez L, Galan M, Falco E, Manzano JL, Gonzalez E, Munoz-Unceta N, Lopez C, Aranda E, Fernandez E, Jorge M, Jimenez-Fonseca P. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. EUROPEAN JOURNAL OF CANCER. 2021. 145():158-167. DOI: 10.1016/j.ejca.2020.12.005.

Autores/as: IF: 9,162 Q1 D2

IF: 9,162

IF: 9,162 Q1 D2

Autores/as: Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Campelo MDG, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M

Título: Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Revista: CLINICAL CANCER RESEARCH

DOI: 10.1158/1078-0432.CCR-21-1200

Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Campelo MDG, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. CLINICAL CANCER RESEARCH. 2021. 27(21):5878-5890. DOI: 10.1158/1078-0432.CCR-21-1200.

Autores/as: IF: 12,531 Q1 D1

IF: 12,531

IF: 12,531 Q1 D1

Autores/as: Sartore-Bianchi A, Garcia-Alfonso P, Geissler M, Kohne CH, Peeters M, Price T, Valladares-Ayerbes M, Zhang Y, Burdon P, Taieb J, Modest DP

Título: Relationships Between Kohne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer

Revista: CLINICAL COLORECTAL CANCER

DOI: 10.1016/j.clcc.2021.05.007

Sartore-Bianchi A, Garcia-Alfonso P, Geissler M, Kohne CH, Peeters M, Price T, Valladares-Ayerbes M, Zhang Y, Burdon P, Taieb J, Modest DP. Relationships Between Kohne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER. 2021. 20(4):305-313. DOI: 10.1016/j.clcc.2021.05.007.

Autores/as: IF: 4,481 Q2 D5

IF: 4,481

IF: 4,481 Q2 D5

Autores/as: Ferre AD, Alvarez RA, Herraez AC, Jurado JC, Gonzalez AE, Martin-Broto J, Marin VM, Vega AM, Garcia AS, Morales CV

Título: SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-020-02534-0

Ferre AD, Alvarez RA, Herraez AC, Jurado JC, Gonzalez AE, Martin-Broto J, Marin VM, Vega AM, Garcia AS, Morales CV. SEOM Clinical Guideline of management of soft-tissue sarcoma (2020). CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(5):922-930. DOI: 10.1007/s12094-020-02534-0.

Autores/as: IF: 3,405 Q3

IF: 3,405

IF: 3,405 Q3

Autores/as: del Alba AG, Mendez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA

Título: SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-021-02561-5

del Alba AG, Mendez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). CLINICAL & TRANSLATIONAL ONCOLOGY. 2021. 23(5):969-979. DOI: 10.1007/s12094-021-02561-5.

Autores/as: IF: 3,405 Q3

IF: 3,405

IF: 3,405 Q3

Autores/as: Gil-Gil M, Alba E, Gavila J, de la Haba-Rodriguez J, Ciruelos E, Tolosa P, Candini D, Llombart-Cussac A

Título: The role of CDK4/6 inhibitors in early breast cancer

Revista: BREAST

DOI: 10.1016/j.breast.2021.05.008

Gil-Gil M, Alba E, Gavila J, de la Haba-Rodriguez J, Ciruelos E, Tolosa P, Candini D, Llombart-Cussac A. The role of CDK4/6 inhibitors in early breast cancer. BREAST. 2021. 58():160-169. DOI: 10.1016/j.breast.2021.05.008.

Autores/as: IF: 4,38 Q1 D2

IF: 4,38

IF: 4,38 Q1 D2

Autores/as: Szabados B, Rodriguez-Vida A, Duran I, Crabb SJ, Van der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez-Vidal MJ, Suarez C, Linch M, Prendergast A, Tyson C, Mousa K, Castellano D, Powles T

Título: Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Revista: EUROPEAN UROLOGY ONCOLOGY

DOI: 10.1016/j.euo.2020.11.010

Szabados B, Rodriguez-Vida A, Duran I, Crabb SJ, Van der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez-Vidal MJ, Suarez C, Linch M, Prendergast A, Tyson C, Mousa K, Castellano D, Powles T. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. EUROPEAN UROLOGY ONCOLOGY. 2021. 4(3):456-463. DOI: 10.1016/j.euo.2020.11.010.

Autores/as: IF: 7,479 Q1 D1

IF: 7,479

IF: 7,479 Q1 D1

Autores/as: Ruedas-Torres I, Rodriguez-Gomez IM, Sanchez-Carvajal JM, Guil-Luna S, Larenas-Munoz F, Pallares FJ, Carrasco L, Gomez-Laguna J

Título: Up-Regulation of Immune Checkpoints in the Thymus of PRRSV-1-Infected Piglets in a Virulence-Dependent Fashion

Revista: FRONTIERS IN IMMUNOLOGY

DOI: 10.3389/fimmu.2021.671743

IF: 7,561

Ruedas-Torres I, Rodriguez-Gomez IM, Sanchez-Carvajal JM, Guil-Luna S, Larenas-Munoz F, Pallares FJ, Carrasco L, Gomez-Laguna J. Up-Regulation of Immune Checkpoints in the Thymus of PRRSV-1-Infected Piglets in a Virulence-Dependent Fashion. FRONTIERS IN IMMUNOLOGY. 2021. 12():-. DOI: 10.3389/fimmu.2021.671743. IF: 7,561 Q1 D2

Autores/as: Camps C, López R, Antón A, Aranda E, Carrato A, Cruz JJ, Cunquero-Tomás AJ, Díaz-Rubio E, Feyjóo M, García-Foncillas J, Gascón P, Lugo I, Rogado Á, Guillem V

Título: Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

Revista: JCO Oncol Pract

DOI: 10.1200/OP.20.00683

Camps C, López R, Antón A, Aranda E, Carrato A, Cruz JJ, Cunquero-Tomás AJ, Díaz-Rubio E, Feyjóo M, García-Foncillas J, Gascón P, Lugo I, Rogado Á, Guillem V. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. JCO Oncol Pract. 2021 Feb 23:OP2000683. doi: 10.1200/OP.20.00683. EAC: LA INCLUYE EL GRUPO. OK

Autores/as: IF: 3,487 Q3

IF: 3,487

IF: 3,487 Q3

Autores/as: Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo JA, Varela MQ, Rubio MJ, Barretina-Ginesta MP, Gonzalez-Martin A

Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo JA, Varela MQ, Rubio MJ, Barretina-Ginesta MP, Gonzalez-Martin A.

Autores/as: SEOM clinical guideline in ovarian cancer (2020)

Título: Clin Transl Oncol

Revista: 2021 May;23(5):961-968

DOI: 10.1007/s12094-020-02545-x

SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol. 2021 May;23(5):961-968. doi: 10.1007/s12094-020-02545-x. EAC: LA INCLUYE EL GRUPO. OK

Autores/as: FI: 2,737 Q3

FI: 2,737 Q3

Autores/as: Andres Redondo, Ana Oaknin, Maria Jesus Rubio, Maria-Pilar Barretina-Ginesta, Ana de Juan, Luis Manso, Ignacio Romero, Cristina Martin-Lorente, Andres Poveda, Antonio Gonzalez-Martin

Título: Management of advanced ovarian cancer in Spain: an expert Delphi consensus

Revista: J Ovarian Res

DOI: 10.1186/s13048-021-00816-x

Andres Redondo, Ana Oaknin, Maria Jesus Rubio, Maria-Pilar Barretina-Ginesta, Ana de Juan, Luis Manso, Ignacio Romero, Cristina Martin-Lorente, Andres Poveda, Antonio Gonzalez-Martin. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. J Ovarian Res. 2021; 14: 72. doi: 10.1186/s13048-021-00816-x EAC: LA INCLUYE EL GRUPO. OK

Autores/as: FI: 6,923 Q1

FI: 6,923 Q1

Autores/as: J

Título: A

Revista: Perez-Fidalgo, A

DOI: 10.1016/j.esmoop.2021.100212

J.A. Perez-Fidalgo, A. Cortés, E. Guerra, Y. García, M. Iglesias, U. Bohn Sarmiento, E. Calvo García, L. Manso Sánchez, A. Santaballa, A. Oaknin, A. Redondo, M.J. Rubio, A. González-Martín. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO Open. 2021 Aug; 6(4): 100212. doi: 10.1016/j.esmoop.2021.100212. EAC: LA INCLUYE EL GRUPO. OK

Autores/as: FI: 5,329 Q1

FI: 5,329 Q1

Autores/as: Guil-Luna S, Mena R, Navarrete-Sirvent C, Lopez-Sanchez LM, Khouadri K, Toledano-Fonseca M, Mantrana A, Guler I, Villar C, Diaz C, Medina-Fernandez FJ, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A,

Título: Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts

Revista: FRONTIERS IN MEDICINE

DOI: 10.3389/fmed.2020.00264

Guil-Luna S, Mena R, Navarrete-Sirvent C, Lopez-Sanchez LM, Khouadri K, Toledano-Fonseca M, Mantrana A, Guler I, Villar C, Diaz C, Medina-Fernandez FJ, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A,. Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts. FRONTIERS IN MEDICINE. 2020. 7 ():- DOI: 10.3389/fmed.2020.00264

Autores/as: IF: 3,9 Q: 1

IF: 3,9

IF: 3,9 Q: 1

Autores/as: Gavila J, De La Haba J, Bermejo B, Rodriguez-Lescure A, Anton A, Ciruelos E, Brunet J, Munoz-Couselo E, Santisteban M, Sanchez CAR, Santaballa A, Rovira PS, Saenz JAG, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanches A, Romera JL, Aguirre E, Co

Título: A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-019-02145-4

Gavila J, De La Haba J, Bermejo B, Rodriguez-Lescure A, Anton A, Ciruelos E, Brunet J, Munoz-Couselo E, Santisteban M, Sanchez CAR, Santaballa A, Rovira PS, Saenz JAG, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanches A, Romera JL, Aguirre E, Co. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (3):420-428 DOI: 10.1007/s12094-019-02145-4

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: Sastre J, de la Orden V, Martinez A, Bando I, Balbin M, Bellosillo B, Palanca S, Gomez MIP, Mediero B, Llovet P, Moral VM, Vieitez JM, Garcia-Alfonso P, Calle SG, Ortiz-Morales MJ, Salud A, Quintero G, Lopez C, Diaz-Rubio E, Aranda E

Título: Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naive Metastatic Colorectal Cancer Patients Prospectively Collected

Revista: CLINICAL COLORECTAL CANCER

DOI: 10.1016/j.clcc.2020.02.014

Sastre J, de la Orden V, Martinez A, Bando I, Balbin M, Bellosillo B, Palanca S, Gomez MIP, Mediero B, Llovet P, Moral VM, Vieitez JM, Garcia-Alfonso P, Calle SG, Ortiz-Morales MJ, Salud A, Quintero G, Lopez C, Diaz-Rubio E, Aranda E. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naive Metastatic Colorectal Cancer Patients Prospectively Collected. CLINICAL COLORECTAL CANCER. 2020. 19 (3):E110-E116 DOI: 10.1016/j.clcc.2020.02.014

Autores/as: IF: 3,245 Q: 3

IF: 3,245

IF: 3,245 Q: 3

Autores/as: Lorente D, Castro E, Lozano R, Puente J, Romero-Laorden N, Rodriguez-Vida A, Lainez N, Villatoro R, Llacer C, Cattrini C, Hernandez A, Domenech M, Zambrana F, Almagro E, Luque R, Martinez E, Lopez-Campos F, Gonzalez B, Mendez-Vidal MJ, Medina A, Piulats J

Título: Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer

Revista: EUROPEAN UROLOGY

DOI: 10.1016/j.eururo.2020.02.025

Lorente D, Castro E, Lozano R, Puente J, Romero-Laorden N, Rodriguez-Vida A, Lainez N, Villatoro R, Llacer C, Cattrini C, Hernandez A, Domenech M, Zambrana F, Almagro E, Luque R, Martinez E, Lopez-Campos F, Gonzalez B, Mendez-Vidal MJ, Medina A, Piulats J. Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer. EUROPEAN UROLOGY. 2020. 77 (6):763-766 DOI: 10.1016/j.eururo.2020.02.025

Autores/as: IF: 17,947 Q: 1 D: 1

IF: 17,947

IF: 17,947 Q: 1 D: 1

Autores/as: Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, Andre T, de Gramont A

Título: Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial

Revista: JAMA NETWORK OPEN

DOI: 10.1001/jamanetworkopen.2020.20425

Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, Andre T, de Gramont A. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial. JAMA NETWORK OPEN. 2020. 3 (10):- DOI: 10.1001/jamanetworkopen.2020.20425

Autores/as: IF: 5,032 Q: 1

IF: 5,032

IF: 5,032 Q: 1

Autores/as: Garcia-Torres F, Jablonski MJ, Solis AG, Jaen-Moreno MJ, Galvez-Lara M, Moriana JA, Moreno-Diaz MJ, Aranda E

Título: Caregiver Burden Domains and Their Relationship with Anxiety and Depression in the First Six Months of Cancer Diagnosis

Revista: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH

DOI: 10.3390/ijerph17114101

Garcia-Torres F, Jablonski MJ, Solis AG, Jaen-Moreno MJ, Galvez-Lara M, Moriana JA, Moreno-Diaz MJ, Aranda E. Caregiver Burden Domains and Their Relationship with Anxiety and Depression in the First Six Months of Cancer Diagnosis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2020. 17 (11):- DOI: 10.3390/ijerph17114101

Autores/as: IF: 2,849 Q: 1

IF: 2,849

IF: 2,849 Q: 1

Autores/as: Toledano-Fonseca M, Cano MT, Inga E, Rodriguez-Alonso R, Gomez-Espana MA, Guil-Luna S, Mena-Osuna R, de la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E

Título: Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer

Revista: CANCERS

DOI: 10.3390/cancers12071754

Toledano-Fonseca M, Cano MT, Inga E, Rodriguez-Alonso R, Gomez-Espana MA, Guil-Luna S, Mena-Osuna R, de la Haba-Rodriguez JR, Rodriguez-Ariza A, Aranda E. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. CANCERS. 2020. 12 (7):- DOI: 10.3390/cancers12071754

Autores/as: IF: 6,126 Q: 1

IF: 6,126

IF: 6,126 Q: 1

Autores/as: Fernandez-Montes A, Gravalos C, Pericay C, Safont MJ, Benavides M, EElez E, Garcia-Alfonso P, Garcia-Paredes B, Carrato A, Aranda E

Título: Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer

Revista: Spanish TTD Group Expert Opinion

DOI: 10.1016/j.clcc.2020.04.003

Fernandez-Montes A, Gravalos C, Pericay C, Safont MJ, Benavides M, EElez E, Garcia-Alfonso P, Garcia-Paredes B, Carrato A, Aranda E. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. CLINICAL COLORECTAL CANCER. 2020. 19 (3):165-177 DOI: 10.1016/j.clcc.2020.04.003

Autores/as: IF: 3,245 Q: 3

IF: 3,245

IF: 3,245 Q: 3

Autores/as: Puente J, Anido U, Climent MA, Gonzalez-Billalabeitia E, Lainez N, Lambea J, Maroto JP, Mendez-Vidal MJ, Montesa A, Rodriguez A, Zambrana C, Gonzalez-del-Alba A

Título: Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

Revista: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

DOI: 10.1177/1758835920920067

Puente J, Anido U, Climent MA, Gonzalez-Billalabeitia E, Lainez N, Lambea J, Maroto JP, Mendez-Vidal MJ, Montesa A, Rodriguez A, Zambrana C, Gonzalez-del-Alba A. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2020. 12 ():- DOI: 10.1177/1758835920920067

Autores/as: IF: 6,852 Q: 1

IF: 6,852

IF: 6,852 Q: 1

Autores/as: Aranda E, Vieitez JM, Gomez-Espana A, Calle SG, Salud-Salvia A, Grana B, Garcia-Alfonso P, Rivera F, Quintero-Aldana GA, Reina-Zoilo JJ, Gonzalez-Flores E, Fernandez MS, Guillen-Ponce C, Garcia-Carbonero R, Safont MJ, Munoa AL, Garcia-Paredes B, Lopez RL, Sastre J, Diaz-Rubio E

Título: FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and >= 3 circulating tumour cells: the randomised phase III VISNu-1 trial

Revista: ESMO OPEN

DOI: 10.1136/esmoopen-2020-000944

Aranda E, Vieitez JM, Gomez-Espana A, Calle SG, Salud-Salvia A, Grana B, Garcia-Alfonso P, Rivera F, Quintero-Aldana GA, Reina-Zoilo JJ, Gonzalez-Flores E, Fernandez MS, Guillen-Ponce C, Garcia-Carbonero R, Safont MJ, Munoa AL, Garcia-Paredes B, Lopez RL, Sastre J, Diaz-Rubio E. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and >= 3 circulating tumour cells: the randomised phase III VISNu-1 trial. ESMO OPEN. 2020. 5 (6):- DOI: 10.1136/esmoopen-2020-000944

Autores/as: IF: 5,329 Q: 1

IF: 5,329

IF: 5,329 Q: 1

Autores/as: Perez-Ruiz E, Jimenez-Castro J, Berciano-Guerrero MA, Valdivia J, Estalella-Mendoza S, Toscano F, Artacho MRD, Garrido-Siles M, Martinez-Bautista MJ, Roldan RV, Rivas-Ruiz F, Nogales-Fernandez E, Morales C, Perez-Valderrama B, De la Cruz-Merino L, Rueda A

Título: Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-020-02315-9

Perez-Ruiz E, Jimenez-Castro J, Berciano-Guerrero MA, Valdivia J, Estalella-Mendoza S, Toscano F, Artacho MRD, Garrido-Siles M, Martinez-Bautista MJ, Roldan RV, Rivas-Ruiz F, Nogales-Fernandez E, Morales C, Perez-Valderrama B, De la Cruz-Merino L, Rueda A. Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (10):1778-1785 DOI: 10.1007/s12094-020-02315-9

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: Artigas L, Coma M, Matos-Filipe P, Aguirre-Plans J, Farres J, Valls R, Fernandez-Fuentes N, de la Haba-Rodriguez J, Olvera A, Barbera J, Morales R, Oliva B, Mas JM

Título: In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

Revista: PLOS ONE

DOI: 10.1371/journal.pone.0240149

Artigas L, Coma M, Matos-Filipe P, Aguirre-Plans J, Farres J, Valls R, Fernandez-Fuentes N, de la Haba-Rodriguez J, Olvera A, Barbera J, Morales R, Oliva B, Mas JM. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLOS ONE. 2020. 15 (10):- DOI: 10.1371/journal.pone.0240149

Autores/as: IF: 2,74 Q: 2

IF: 2,74

IF: 2,74 Q: 2

Autores/as: Gonzalez-del-Alba A, Arranz JA, Bellmunt J, Maroto JP, Fernandez-Calvo O, Valderrama BP, Gonzalez-Billalabeitia E, Mendez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MA, Puentel J, Pelaez I, Lazaro-Quintela M, Gallardo E, Suarez C

Título: Latest progress in molecular biology and treatment in genitourinary tumours

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-020-02373-z

Gonzalez-del-Alba A, Arranz JA, Bellmunt J, Maroto JP, Fernandez-Calvo O, Valderrama BP, Gonzalez-Billalabeitia E, Mendez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MA, Puentel J, Pelaez I, Lazaro-Quintela M, Gallardo E, Suarez C. Latest progress in molecular biology and treatment in genitourinary tumours. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (12):2175-2195 DOI: 10.1007/s12094-020-02373-z

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Pereira E, Royuela A, Casarrubios M, Anton CS, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermudez A

Título: Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Revista: LANCET ONCOLOGY

DOI: 10.1016/S1470-2045(20)30453-8

Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Pereira E, Royuela A, Casarrubios M, Anton CS, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermudez A. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2020. 21 (11):1413-1422 DOI: 10.1016/S1470-2045(20)30453-8

Autores/as: IF: 33,752 Q: 1 D: 1

IF: 33,752

IF: 33,752 Q: 1 D: 1

Autores/as: Lopez-Sanchez LM, Aranda E, Rodriguez-Ariza A

Título: Nitric oxide and tumor metabolic reprogramming

Revista: BIOCHEMICAL PHARMACOLOGY

DOI: 10.1016/j.bcp.2019.113769

Lopez-Sanchez LM, Aranda E, Rodriguez-Ariza A. Nitric oxide and tumor metabolic reprogramming. BIOCHEMICAL PHARMACOLOGY. 2020. 176 ():- DOI: 10.1016/j.bcp.2019.113769

Autores/as: IF: 4,96 Q: 1 D: 1

IF: 4,96

IF: 4,96 Q: 1 D: 1

Autores/as: Viudez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernandez R, Cano JM, Macias I, Custodio A, de Castro EM, Sanchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sanchez-Canovas M, Mangas M, Limon ML, Martinez-Torron A, Asensio E, Ramchandani A, Martin-Carnicero, A (Martin-Carnicero, A

Título: )[ 20 ] ; Hurtado, A (Hurtado, A

Revista: )[ 21 ] ; Cerda, P (Cerda, P

DOI: 10.1007/s12094-019-02183-y

Viudez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernandez R, Cano JM, Macias I, Custodio A, de Castro EM, Sanchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sanchez-Canovas M, Mangas M, Limon ML, Martinez-Torron A, Asensio E, Ramchandani A, Martin-Carnicero, A (Martin-Carnicero, A.)[ 20 ] ; Hurtado, A (Hurtado, A.)[ 21 ] ; Cerda, P (Cerda, P.)[ 22 ] ; Garrido, M (Garrido, M.)[ 23 ] ; Sanchez-Bayonas, R (Sanchez-Bayonas, R.)[ 24 ] ; Serrano, R (Serrano, R.)[ 25 ] ; Jimenez-Fonseca, P (Jimenez-Fonseca, P.)[ 26 ] . Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (5):734-750 DOI: 10.1007/s12094-019-02183-y

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: Carrato A, Vieitez JM, Benavides M, Rodriguez-Garrote M, Castillo A, Ogalla GD, Bermejo LG, de Mena IR, Guillen-Ponce C, Aranda E

Título: Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results

Revista: EUROPEAN JOURNAL OF CANCER

DOI: 10.1016/j.ejca.2020.07.035

Carrato A, Vieitez JM, Benavides M, Rodriguez-Garrote M, Castillo A, Ogalla GD, Bermejo LG, de Mena IR, Guillen-Ponce C, Aranda E. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. EUROPEAN JOURNAL OF CANCER. 2020. 139 ():51-58 DOI: 10.1016/j.ejca.2020.07.035

Autores/as: IF: 7,275 Q: 1

IF: 7,275

IF: 7,275 Q: 1

Autores/as: Salazar R, Capdevila J, Manzano JL, Pericay C, Martinez-Villacampa M, Lopez C, Losa F, Safont MJ, Gomez-Espana A, Alonso-Orduna V, Escudero P, Gallego J, Garcia-Paredes B, Palacios A, Biondo S, Gravalos C, Aranda E

Título: Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results

Revista: BMC CANCER

DOI: 10.1186/s12885-020-07661-z

Salazar R, Capdevila J, Manzano JL, Pericay C, Martinez-Villacampa M, Lopez C, Losa F, Safont MJ, Gomez-Espana A, Alonso-Orduna V, Escudero P, Gallego J, Garcia-Paredes B, Palacios A, Biondo S, Gravalos C, Aranda E. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. BMC CANCER. 2020. 20 (1):- DOI: 10.1186/s12885-020-07661-z

Autores/as: IF: 3,15 Q: 3

IF: 3,15

IF: 3,15 Q: 3

Autores/as: Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz JA, Torres R, de la Haba J, Garcia-Martinez E, Gomez HL, Llombart A, Bofill JS, Baena-Canada JM, Barnadas A, Calvo L, Perez-Michel L, Ramos M, Fernande

Título: Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Revista: JOURNAL OF CLINICAL ONCOLOGY

DOI: 10.1200/JCO.19.00904

Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz JA, Torres R, de la Haba J, Garcia-Martinez E, Gomez HL, Llombart A, Bofill JS, Baena-Canada JM, Barnadas A, Calvo L, Perez-Michel L, Ramos M, Fernande. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38 (3):203-213 DOI: 10.1200/JCO.19.00904

Autores/as: IF: 32,956 Q: 1 D: 1

IF: 32,956

IF: 32,956 Q: 1 D: 1

Autores/as: Lazaro M, Valderrama BP, Suarez C, de-Velasco G, Beato C, Chirivella I, Gonzalez-Del-Alba A, Lainez N, Mendez-Vidal MJ, Arranz JA

Título: SEOM clinical guideline for treatment of kidney cancer (2019)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-019-02285-7

Lazaro M, Valderrama BP, Suarez C, de-Velasco G, Beato C, Chirivella I, Gonzalez-Del-Alba A, Lainez N, Mendez-Vidal MJ, Arranz JA. SEOM clinical guideline for treatment of kidney cancer (2019). CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (2):256-269 DOI: 10.1007/s12094-019-02285-7

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: Guillen-Ponce C, Lastra E, Lorenzo-Lorenzo I, Gomez TM, Chamorro RM, Sanchez-Heras AB, Serrano R, Rodriguez MCS, Soto JL, Robles L

Título: SEOM clinical guideline on hereditary colorectal cancer (2019)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-019-02272-y

Guillen-Ponce C, Lastra E, Lorenzo-Lorenzo I, Gomez TM, Chamorro RM, Sanchez-Heras AB, Serrano R, Rodriguez MCS, Soto JL, Robles L. SEOM clinical guideline on hereditary colorectal cancer (2019). CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (2):201-212 DOI: 10.1007/s12094-019-02272-y

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: Gallardo E, Medina J, Sanchez JC, Viudez A, Grande E, Porras I, Ramon y Cajal T, Trigo J, Iglesias L, Capdevila J

Título: SEOM clinical guideline thyroid cancer (2019)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-019-02284-8

Gallardo E, Medina J, Sanchez JC, Viudez A, Grande E, Porras I, Ramon y Cajal T, Trigo J, Iglesias L, Capdevila J. SEOM clinical guideline thyroid cancer (2019). CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (2):223-235 DOI: 10.1007/s12094-019-02284-8

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: Garcia-Torres F, Jablonski MJ, Solis AG, Moriana JA, Jaen-Moreno MJ, Moreno-Diaz MJ, Aranda E

Título: Social support as predictor of anxiety and depression in cancer caregivers six months after cancer diagnosis: A longitudinal study

Revista: JOURNAL OF CLINICAL NURSING

DOI: 10.1111/jocn.15123

Garcia-Torres F, Jablonski MJ, Solis AG, Moriana JA, Jaen-Moreno MJ, Moreno-Diaz MJ, Aranda E. Social support as predictor of anxiety and depression in cancer caregivers six months after cancer diagnosis: A longitudinal study. JOURNAL OF CLINICAL NURSING. 2020. 29 (5-6):996-1002 DOI: 10.1111/jocn.15123

Autores/as: IF: 1,972 Q: 1

IF: 1,972

IF: 1,972 Q: 1

Autores/as: Rodriguez-Lescure A, de la Pena FA, Aranda E, Calvo A, Felip E, Garrido P, Vera R

Título: Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-020-02366-y

Rodriguez-Lescure A, de la Pena FA, Aranda E, Calvo A, Felip E, Garrido P, Vera R. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (12):2253-2263 DOI: 10.1007/s12094-020-02366-y

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: de las Heras BB, Cajal JCRY, Calvo EG, Rodriguez JD, Mata JG, Anton FM, Fernandez IP, Rodriguez-Lescure A, Sanchez CAR, Ruiz-Borrego M, Remak E, Barra M, Rivero M, Alvarez JS

Título: The economic burden of metastatic breast cancer in Spain

Revista: EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE

DOI: 10.1136/ejhpharm-2017-001453

de las Heras BB, Cajal JCRY, Calvo EG, Rodriguez JD, Mata JG, Anton FM, Fernandez IP, Rodriguez-Lescure A, Sanchez CAR, Ruiz-Borrego M, Remak E, Barra M, Rivero M, Alvarez JS. The economic burden of metastatic breast cancer in Spain. EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE. 2020. 27 (1):19-24 DOI: 10.1136/ejhpharm-2017-001453

Autores/as: IF: 0,892 Q: 4

IF: 0,892

IF: 0,892 Q: 4

Autores/as: Aranda E, Polo E, Camps C, Carrato A, Diaz-Rubio E, Guillem V, Lopez R, Anton A

Título: Treatment patterns for metastatic colorectal cancer in Spain

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-019-02279-5

Aranda E, Polo E, Camps C, Carrato A, Diaz-Rubio E, Guillem V, Lopez R, Anton A. Treatment patterns for metastatic colorectal cancer in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2020. 22 (9):1455-1462 DOI: 10.1007/s12094-019-02279-5

Autores/as: IF: 2,737 Q: 3

IF: 2,737

IF: 2,737 Q: 3

Autores/as: Correa-Saez A, Jimenez-Izquierdo R, Garrido-Rodriguez M, Morrugares R, Munoz E, Calzado MA

Título: Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases

Revista: CELLULAR AND MOLECULAR LIFE SCIENCES

DOI: 10.1007/s00018-020-03556-1

Correa-Saez A, Jimenez-Izquierdo R, Garrido-Rodriguez M, Morrugares R, Munoz E, Calzado MA. Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases. CELLULAR AND MOLECULAR LIFE SCIENCES. 2020. 77 (23):4747-4763 DOI: 10.1007/s00018-020-03556-1

Autores/as: IF: 6,496 Q: 1

IF: 6,496

IF: 6,496 Q: 1

Autores/as: Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S

Título: Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis

Revista: MOLECULAR NUTRITION & FOOD RESEARCH

DOI: 10.1002/mnfr.201800864

Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S. Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 2019. 63. 9. DOI:10.1002/mnfr.201800864.

Autores/as: IF: 5,151 D: 1

IF: 5,151

IF: 5,151 D: 1

Autores/as: Penarando J, Aranda E, Rodriguez-Ariza A

Título: Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response

Revista: TRANSLATIONAL RESEARCH

DOI: 10.1016/j.trs1.2019.03.003

Penarando J, Aranda E, Rodriguez-Ariza A. Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response. TRANSLATIONAL RESEARCH. 2019. 210. 99-108. DOI:10.1016/j.trs1.2019.03.003.

Autores/as: IF: 4,915 D: 1

IF: 4,915

IF: 4,915 D: 1

Autores/as: Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Gravalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, Lopez C, Alonso B, de Mena IR, Diaz-Rubio E, Tabernero J, Aranda E

Título: A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

Revista: BRITISH JOURNAL OF CANCER

DOI: 10.1038/s41416-019-0537-z

Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Gravalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, Lopez C, Alonso B, de Mena IR, Diaz-Rubio E, Tabernero J, Aranda E. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. BRITISH JOURNAL OF CANCER. 2019. 121. 5. 378-383. DOI:10.1038/s41416-019-0537-z.

Autores/as: IF: 5,416 Q: 1

IF: 5,416

IF: 5,416 Q: 1

Autores/as: Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A

Título: SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours

Revista: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

DOI: 10.1111/jcmm.14693

Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A. SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. . 0. DOI:10.1111/jcmm.14693.

Autores/as: IF: 4,658 Q: 1

IF: 4,658

IF: 4,658 Q: 1

Autores/as: Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Alfonso PG, Falco E, Reboredo M, Cano T, Gallego J, Vieitez JM, Layos L, Salud A, Polo E, Dotor E, Duran-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E

Título: First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Revista: BMC CANCER

DOI: 10.1186/s12885-019-5753-7

Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Alfonso PG, Falco E, Reboredo M, Cano T, Gallego J, Vieitez JM, Layos L, Salud A, Polo E, Dotor E, Duran-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC CANCER. 2019. 19. DOI:10.1186/s12885-019-5753-7.

Autores/as: IF: 2,933 Q: 3

IF: 2,933

IF: 2,933 Q: 3

Autores/as: Gomez-Espana MA, Gallego J, Gonzalez-Flores E, Maurel J, Paez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R

Título: SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-018-02002-w

Gomez-Espana MA, Gallego J, Gonzalez-Flores E, Maurel J, Paez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). CLINICAL & TRANSLATIONAL ONCOLOGY. 2019. 21. 1. 46-54. DOI:10.1007/s12094-018-02002-w.

Autores/as: IF: 2,441 Q: 3

IF: 2,441

IF: 2,441 Q: 3

Autores/as: Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J

Título: Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy

Revista: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY

DOI: 10.2174/1871520619666190417162409

Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J. Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 2019. 19. 11. 1388-1398. DOI:10.2174/1871520619666190417162409.

Autores/as: IF: 2,18 Q: 3

IF: 2,18

IF: 2,18 Q: 3

Autores/as: Ciruelos E, Perez-Garcia JM, Gavila J, Rodriguez A, de la Haba-Rodriguez J

Título: Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept

Revista: CLINICAL DRUG INVESTIGATION

DOI: 10.1007/s40261-019-00790-9

Ciruelos E, Perez-Garcia JM, Gavila J, Rodriguez A, de la Haba-Rodriguez J. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept. CLINICAL DRUG INVESTIGATION. 2019. 39. 7. 595-606. DOI:10.1007/s40261-019-00790-9.

Autores/as: IF: 1,918 Q: 3

IF: 1,918

IF: 1,918 Q: 3

Autores/as: Abad A, Martinez-Balibrea E, Vieitez JM, Alonso-Orduna V, Alfonso PG, Manzano JL, Massuti B, Benavides M, Carrato A, Zanui M, Gallego J, Gravalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E

Título: Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

Revista: ANNALS OF ONCOLOGY

Abad A, Martinez-Balibrea E, Vieitez JM, Alonso-Orduna V, Alfonso PG, Manzano JL, Massuti B, Benavides M, Carrato A, Zanui M, Gallego J, Gravalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. ANNALS OF ONCOLOGY. 2018; 29(2):439-444.

Autores/as: IF: 13,926 Q: 1 D: 1

IF: 13,926

IF: 13,926 Q: 1 D: 1

Autores/as: Penarando J, Lopez-Sanchez LM, Mena R, Guil-Luna S, Conde F, Hernandez V, Toledano M, Gudino V, Raponi M, Billard C, Villar C, Diaz C, Gomez-Barbadillo J, De la Haba-Rodriguez J, Myant K, Aranda E, Rodriguez-Ariza A

Título: A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer

Revista: BMC BIOLOGY

Penarando J, Lopez-Sanchez LM, Mena R, Guil-Luna S, Conde F, Hernandez V, Toledano M, Gudino V, Raponi M, Billard C, Villar C, Diaz C, Gomez-Barbadillo J, De la Haba-Rodriguez J, Myant K, Aranda E, Rodriguez-Ariza A. A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. BMC BIOLOGY. 2018; 16:Núm artículo 3

Autores/as: IF: 5,77 Q: 1 D: 1

IF: 5,77

IF: 5,77 Q: 1 D: 1

Autores/as: Aranda E, Garcia-Alfonso P, Benavides M, Ruiz AS, Guillen-Ponce C, Safont MJ, Alcaide J, Gomez A, Lopez R, Manzano JL, Urena MM, Sastre J, Rivera F, Gravalos C, Garcia T, Martin-Valades JI, Falco E, Navalon M, Flores EG, Tapiador AMG, Munoz AML, Barrajon E, Reboredo M, Teijido PG, Viudez A, Cardenas N, Diaz-Rubio E

Título: First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Revista: EUROPEAN JOURNAL OF CANCER

Aranda E, Garcia-Alfonso P, Benavides M, Ruiz AS, Guillen-Ponce C, Safont MJ, Alcaide J, Gomez A, Lopez R, Manzano JL, Urena MM, Sastre J, Rivera F, Gravalos C, Garcia T, Martin-Valades JI, Falco E, Navalon M, Flores EG, Tapiador AMG, Munoz AML, Barrajon E, Reboredo M, Teijido PG, Viudez A, Cardenas N, Diaz-Rubio E. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. EUROPEAN JOURNAL OF CANCER. 2018; 101:263-272.

Autores/as: IF: 7,191 Q: 1

IF: 7,191

IF: 7,191 Q: 1

Autores/as: Garcia-Alfonso P, Benavides M, Falco E, Munoz A, Gomez A, Sastre J, Rivera F, Montagut C, Salgado M, Lopez-Ladron A, Lopez R, de Mena IR, Duran G, Aranda E

Título: Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

Revista: ONCOLOGIST

Garcia-Alfonso P, Benavides M, Falco E, Munoz A, Gomez A, Sastre J, Rivera F, Montagut C, Salgado M, Lopez-Ladron A, Lopez R, de Mena IR, Duran G, Aranda E. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ONCOLOGIST. 2018; 23(11):1271-e128.

Autores/as: IF: 5,306 Q: 1

IF: 5,306

IF: 5,306 Q: 1

Autores/as: Alsina M, Rivera F, Ramos FJ, Galan M, Lopez R, Garcia-Alfonso P, Ales-Martinez JE, Queralt B, Anton A, Carrato A, Gravalos C, Mendez-Vidal MJ, Lopez C, de Mena IR, Tabernero J, Giralt J, Aranda E

Título: A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients

Revista: TARGETED ONCOLOGY

Alsina M, Rivera F, Ramos FJ, Galan M, Lopez R, Garcia-Alfonso P, Ales-Martinez JE, Queralt B, Anton A, Carrato A, Gravalos C, Mendez-Vidal MJ, Lopez C, de Mena IR, Tabernero J, Giralt J, Aranda E. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. TARGETED ONCOLOGY. 2018; 13(1):69-78.

Autores/as: IF: 3,877 Q: 2

IF: 3,877

IF: 3,877 Q: 2

Autores/as: De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E

Título: Humanized Mice for the Study of Immuno-Oncology

Revista: TRENDS IN IMMUNOLOGY

De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized Mice for the Study of Immuno-Oncology. TRENDS IN IMMUNOLOGY. 2018; 39(9):748-763.

Autores/as: IF: 14,188 Q: 1 D: 1

IF: 14,188

IF: 14,188 Q: 1 D: 1

Autores/as: Gravalos C, Carrato A, Tobena M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limon ML, Safont MJ, de Castro EM, Garcia-Alfonso P, Aranda E

Título: A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer

Revista: CLINICAL COLORECTAL CANCER

Gravalos C, Carrato A, Tobena M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limon ML, Safont MJ, de Castro EM, Garcia-Alfonso P, Aranda E. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER. 2018; 17(2):E323-E329.

Autores/as: IF: 3,861 Q: 2

IF: 3,861

IF: 3,861 Q: 2

Autores/as: Munoz AP, Garcia JMC, Rubio MDT, Vicente AMG, Pardo FJP, Londono GAJ, Castrejon AS, Aguilar EA

Título: Value of [F-18]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages

Revista: MEDICINE; 2018:97(17):Núm artículo e0098

Munoz AP, Garcia JMC, Rubio MDT, Vicente AMG, Pardo FJP, Londono GAJ, Castrejon AS, Aguilar EA. Value of [F-18]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages. MEDICINE; 2018:97(17):Núm artículo e0098

Autores/as: IF: 2,028 Q: 2

IF: 2,028

IF: 2,028 Q: 2

Autores/as: Mendez-Vidal MJ, Molina A, Anido U, Chirivella I, Etxaniz O, Fernandez-Parra E, Guix M, Hernandez C, Lambea J, Montesa A, Pinto A, Ros S, Gallardo E

Título: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Revista: BMC PHARMACOLOGY & TOXICOLOGY

Mendez-Vidal MJ, Molina A, Anido U, Chirivella I, Etxaniz O, Fernandez-Parra E, Guix M, Hernandez C, Lambea J, Montesa A, Pinto A, Ros S, Gallardo E. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC PHARMACOLOGY & TOXICOLOGY. 2018; 19:Núm artículo 77

Autores/as: IF: 1,865 Q: 3

IF: 1,865

IF: 1,865 Q: 3

Autores/as: Munoz AP, Garcia JMC, Rubio PT, Vicente AMG, Garcia BG, Guardia MEB, Castrejon AS, Aguilard EA

Título: Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose [F-18] FDG) in the detection of recurrent ovarian cancer

Revista: MEDICINA CLINICA

Munoz AP, Garcia JMC, Rubio PT, Vicente AMG, Garcia BG, Guardia MEB, Castrejon AS, Aguilard EA. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose [F-18] FDG) in the detection of recurrent ovarian cancer. MEDICINA CLINICA. 2018; 151(3):97-102.

Autores/as: IF: 1,168 Q: 3

IF: 1,168

IF: 1,168 Q: 3

Autores/as: Lopez RL, Herrero CC, Khosravi-Shahi P, Porta VG, Mena AC, Garcia-Foncillas J, Hernandez JJC, Vilaplana PG, Torres AA, Diaz-Rubio E, Saus MF, Aguilar EA

Título: Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

Lopez RL, Herrero CC, Khosravi-Shahi P, Porta VG, Mena AC, Garcia-Foncillas J, Hernandez JJC, Vilaplana PG, Torres AA, Diaz-Rubio E, Saus MF, Aguilar EA. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(5):613-618.

Autores/as: IF: 2,392 Q: 3

IF: 2,392

IF: 2,392 Q: 3

Autores/as: Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G

Título: First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial

Revista: JOURNAL OF CLINICAL ONCOLOGY

Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(28):2826-2835.

Autores/as: IF: 26,303 Q: 1 D: 1

IF: 26,303

IF: 26,303 Q: 1 D: 1

Autores/as: Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Zalcberg JR

Título: Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

Revista: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Zalcberg JR. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018; 110(6):638-648.

Autores/as: IF: 11,238 Q: 1 D: 1

IF: 11,238

IF: 11,238 Q: 1 D: 1

Autores/as: Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL

Título: Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database

Revista: EUROPEAN JOURNAL OF CANCER

Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018; 103:205-213.

Autores/as: IF: 7,191 Q: 1

IF: 7,191

IF: 7,191 Q: 1

Autores/as: van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M

Título: Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database

Revista: EUROPEAN JOURNAL OF CANCER

van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018; 91:99-106.

Autores/as: IF: 7,191 Q: 1

IF: 7,191

IF: 7,191 Q: 1

Autores/as: Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, Lopez R, Muinelo-Romay L, Montagut C, Anton A, Lopez G, Diaz-Rubio E, Rojo F, Vivancos A

Título: Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

Revista: BRITISH JOURNAL OF CANCER

Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, Lopez R, Muinelo-Romay L, Montagut C, Anton A, Lopez G, Diaz-Rubio E, Rojo F, Vivancos A. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. BRITISH JOURNAL OF CANCER. 2018; 119(12):1464-1470.

Autores/as: IF: 5,922 Q: 1

IF: 5,922

IF: 5,922 Q: 1

Autores/as: Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuno FM, Guillen-Ponce C, Rojas I, Arande E, Torres C, Prados J

Título: Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers

Revista: PLOS ONE

Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuno FM, Guillen-Ponce C, Rojas I, Arande E, Torres C, Prados J. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. PLOS ONE. 2018; 13(4):Núm artículo e0194844

Autores/as: IF: 2,766 Q: 1

IF: 2,766

IF: 2,766 Q: 1

Autores/as: Arriola E, Gomez RG, Diz P, Majem M, Aguillo MM, Valdivia J, Paredes A, Sanchez-Torres JM, Munoz SP, Barneto I, Gutierrez V, Santiago JMA, Aparisi F, Isla D, Ponce S, Baz DV, Artal A, Amador M, Provencio M

Título: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Revista: BMC CANCER 2018; 18:Núm artículo 106

Arriola E, Gomez RG, Diz P, Majem M, Aguillo MM, Valdivia J, Paredes A, Sanchez-Torres JM, Munoz SP, Barneto I, Gutierrez V, Santiago JMA, Aparisi F, Isla D, Ponce S, Baz DV, Artal A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC CANCER 2018; 18:Núm artículo 106

Autores/as: IF: 3,288 Q: 2

IF: 3,288

IF: 3,288 Q: 2

Autores/as: Arjona-Sanchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martin VC, Garcia-Fadrique A, Gutierrez-Calvo A, Morales R, Ortega-Perez G, Perez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sanchez-Hidalgo JM, Casado-Adam A, Garcia-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna MT, Diaz-Lopez C, Torres-Tordera E, Briceno-Delgado FJ, Rufian-Pena S

Título: HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma

Revista: BMC CANCER

Arjona-Sanchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martin VC, Garcia-Fadrique A, Gutierrez-Calvo A, Morales R, Ortega-Perez G, Perez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sanchez-Hidalgo JM, Casado-Adam A, Garcia-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna MT, Diaz-Lopez C, Torres-Tordera E, Briceno-Delgado FJ, Rufian-Pena S. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC CANCER. 2018; 18:Núm artículo 183

Autores/as: IF: 3,288 Q: 2

IF: 3,288

IF: 3,288 Q: 2

Autores/as: Castellano D, Maroto JP, Espinosa E, Grande E, Bolos MV, Llinares J, Esteban E, del Alba AG, Climent MA, Arranz JA, Mendez MJ, Parra EF, Anton-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, Donas JG

Título: Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

Revista: EXPERT OPINION ON DRUG SAFETY

Castellano D, Maroto JP, Espinosa E, Grande E, Bolos MV, Llinares J, Esteban E, del Alba AG, Climent MA, Arranz JA, Mendez MJ, Parra EF, Anton-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, Donas JG. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. EXPERT OPINION ON DRUG SAFETY. 2018; 17(6):573-579.

Autores/as: IF: 3,156 Q: 2

IF: 3,156

IF: 3,156 Q: 2

Autores/as: Caries J, Castellano D, Mendez-Vidal MJ, Mellado B, Saez MI, del Alba AG, Perez-Gracia JL, Jimenez J, Suarez C, Sepulveda JM, Manneh R, Porras I, Lopez C, Morales-Barrera R, Arranz JA

Título: Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer

Revista: CLINICAL GENITOURINARY CANCER

Caries J, Castellano D, Mendez-Vidal MJ, Mellado B, Saez MI, del Alba AG, Perez-Gracia JL, Jimenez J, Suarez C, Sepulveda JM, Manneh R, Porras I, Lopez C, Morales-Barrera R, Arranz JA. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. CLINICAL GENITOURINARY CANCER. 2018; 16(6):E1133-E1139.

Autores/as: IF: 2,539 Q: 2

IF: 2,539

IF: 2,539 Q: 2

Autores/as: Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cadenas-Rebollo JM, Garcia-Garcia A, Gil-Ibanez B, Juan-Fita MJ, Patrono MG

Título: Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cadenas-Rebollo JM, Garcia-Garcia A, Gil-Ibanez B, Juan-Fita MJ, Patrono MG. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(10):1337-1344.

Autores/as: IF: 2,392 Q: 3

IF: 2,392

IF: 2,392 Q: 3

Autores/as: Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, Sepulveda-Sanchez JM, Campayo M, Chirivella-Gonzalez I, Garcia-del-Muro X, Gonzalez-Del-Alba A, Grande E, Suarez C

Título: SEOM clinical guideline for treatment of kidney cancer (2017)

Revista: CLINICAL & TRANSLATIONAL ONCOLOGY

Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, Sepulveda-Sanchez JM, Campayo M, Chirivella-Gonzalez I, Garcia-del-Muro X, Gonzalez-Del-Alba A, Grande E, Suarez C. SEOM clinical guideline for treatment of kidney cancer (2017). CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(1):47-56.

Autores/as: IF: 2,392 Q: 3

IF: 2,392

IF: 2,392 Q: 3

Autores/as: Carles J, Mendez MJ, Pinto A, Saez MI, Arranz JA, Maroto P, Lopez-Criado P, Mellado B, Donas JG, Hernando S, Leon L, del Alba AG, Lainez N, Esteban E, Reynes G, Perez-Gracia JL, Germa JR, Lopez-Brea M, Perez-Valderrama B, Moretones C, Castellano D

Título: Radium-223 international early access program: results from the Spanish subset

Revista: FUTURE ONCOLOGY

Carles J, Mendez MJ, Pinto A, Saez MI, Arranz JA, Maroto P, Lopez-Criado P, Mellado B, Donas JG, Hernando S, Leon L, del Alba AG, Lainez N, Esteban E, Reynes G, Perez-Gracia JL, Germa JR, Lopez-Brea M, Perez-Valderrama B, Moretones C, Castellano D. Radium-223 international early access program: results from the Spanish subset. FUTURE ONCOLOGY. 2018; 14(1):41-50.

Autores/as: IF: 2,369 Q: 3

IF: 2,369

IF: 2,369 Q: 3

Autores/as: Garcia-Borruel MM, Molina AJH, Peralvarez MLR, Rincon EM, Medrano IP, Ruiz FJS, Juanena LLC, Navarro MP, Rodriguez AN, Pastor CV

Título: Post-colonoscopy colorectal cancer: Characteristics and predictive factors

Revista: MEDICINA CLINICA

Garcia-Borruel MM, Molina AJH, Peralvarez MLR, Rincon EM, Medrano IP, Ruiz FJS, Juanena LLC, Navarro MP, Rodriguez AN, Pastor CV. Post-colonoscopy colorectal cancer: Characteristics and predictive factors. MEDICINA CLINICA. 2018; 150(1):1-7.

Autores/as: IF: 1,168 Q: 3

IF: 1,168

IF: 1,168 Q: 3